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Abstract
Specificity in the Druggable Kinome: Molecular Basis and its Applications
by
Xi Zhang
Rational design of kinase inhibitors remains a challenge partly because there is no clear
delineation of the molecular features that direct the pharmacological impact towards clini-
cally relevant targets. In this thesis, we focus on a structural marker and construct a kinase
classifier that enables the accurate prediction of pharmacological differences. Our indica-
tor is a microenvironmental descriptor that quantifies the propensity for water exclusion
around preformed polar pairs. The results suggest that targeting polar dehydration patterns
heralds a new generation of drugs that enable a tighter control of specificity than designs
aimed at promoting ligand-kinase pairwise interactions.
As an application of the structural marker, we introduce a computational screening ap-
proach which provides a tool for extensive screening that uses experimentally obtained
small-scale profiles as input data and makes predictions for a larger kinase set. These pre-
dictions result from a propagation of the reduced profile, exploiting a structural comparison
of kinases based on a feature-similarity matrix. The comparison focuses on a molecular
marker for specificity and promiscuity of kinase inhibitors. Our approach enables the com-
putational high-throughput screening of entire libraries of compounds to search for suitable
leads, mapping their inhibitory impact on a sizable sample of the human kinome.
Yet another application of the structural marker is advocated by illustrating its cleaning
efficacy. In this regard, we reassess the possibility to turn multi-target drugs into real clin-
ical opportunities through judicious redesign. A general cleaning strategy, which adopts
the structural marker as redesigning intruction, is proposed and exemplified by a workable
approach.
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Chapter 1
Introduction
Kinase targeting is a central theme in drug discovery and molecular cancer therapy
(Bain et al., 2003; Druker, 2004; Hopkins et al., 2006; Huse and Kuriyan, 2002; Knight
and Shokat, 2005; Vieth et al., 2004), but a structural basis for rational design appears to be
inconclusive (Bain et al., 2003; Hopkins et al., 2006; Huse and Kuriyan, 2002; Vieth et al.,
2004). In practice, most ligands or drug leads are actually discovered through large-scale
experimental screenings (Drews, 2000; Bleicher et al., 2003). This is part of the reason
why development of new drugs remains an expensive process. While the paradigm of target
specificity (Bain et al., 2003; Huse and Kuriyan, 2002) may be shifting to controlled multi-
target impact (Hopkins et al., 2006), the structural factors determining these possibilities
are not yet fully understood, in spite of notable progress. For instance, the accessible
nonpolar surface, frequently invoked to assess protein associations (Chothia, 1974; Whittle
and Blundell, 1994), actually fosters promiscuity (Feng et al., 2005; Hopkins et al., 2006),
as shown in the work presented in this thesis.
1
2The main subject of the research presented in this thesis is to investigate the promis-
cuity and specificity in the druggable kinome. In this regrad, the research includes three
major parts. First, we managed to identify the molecular basis of the promiscuity and
specificity of the kinase inhibition. Based on our discovery, we developed two practical
applications that exploit the structural feature governing the specificity of inhibition. That
is, we developed an in silico drug profile predictor and a technique to turn promiscuous
kinase inhibitors into safer drugs.
As the first step, we focus on identifying the dominant molecular feature that directs
nonpromiscuous drug targeting. The identification is based on the comparison of a series
of metrics that measure the differences between kinases in different senses respectively.
One metric is defined to quantify the differentness between two kinases in the sense of
their affinity profiles for kinase inhibitors. Several other metrics are defined to quantify
the differentnesses between two kinases in their structural attributes. The essential idea
to identify the molecular feature governing specific drug targeting is as follows. For any
of such specificity-governing molecular features, the metric measuring the differences be-
tween kinases in the sense of this feature should be correlated with the metric quantifying
the differentness between kinases in the sense of their affinity profiles for kinase inhibitors.
Starting from this straightforward idea, we found a special type of hydrogen bond as the
molecular basis for specificity in kinase inhibitors.
Promiscuity is operationally defined based on extensive drug screening (Fabian et al.,
2005) as significant cross reactivity (dissociation constant Kd < 100nM) extended over
30% of the sampled kinome. The problem is complicated due to the scarcity of affinity-
profiled kinases with reported structure: To date, only about 20% of the human kinome
3(about 100 out of the 520 discovered protein kinases) is reported in the PDB. Further-
more, kinase homology models are not useful to make sequence-based inferences since the
level of sequence identity across the kinase superfamily is typically low (<30%, Manning
et al., 2002). Instead, we take advantage of the high degree of conservation of kinase folds,
arising from their common ancestry. Thus, reliable sequence-based attributes such as dis-
order propensity (Braken et al., 2004) are here mapped onto structurally threaded models
(Fernández and Berry, 2004) to make inferences about drug specificity/promiscuity.
We search for a sequence-based attribute that enables a classification of kinase space
that accurately reproduces similarities/differences in affinity profiling against a drug back-
ground (Fabian et al., 2005). Our methodology could be implemented because the relevant
classification of kinases was performed by comparing the regions deprived of adequate
packing or intramolecular dehydration, i.e. the loopy regions, which are precisely the
markers differentiating kinases at the structural level (Huse and Kuriyan, 2002).
Having identified structural marker governing specificity, we further exploited the dis-
covery and introduced a comparison of the structural marker patterns of kinases including
purported targets and experimentally confirmed targets. Based on this comparison, we
developed a predictive profiler in which the comparison is adopted as surrogate for the
differences in their pharmacological behavior. The core of our affinity-profile predictor
involves determining a linear propagator of profiling data. This propagator consists of the
structure-based estimation of pharmacological distances across kinases. Once the propa-
gator is computed, the inference of affinity profiles for test drugs becomes a problem in
distance geometry.
While the first application is adopting the structural marker in a macro manner, the
4second application is conducted in a micro (case-by-case) manner. In this application, we
come up with a general strategy to clean promiscuous inhibitors by introducing “wrap-
ping” chemical modifications that preserve the drug chemotype while targeting unique de-
hydrons. As an operational illustration, we focus on redesigning a promiscuous compound,
EKB-569, to enhance its selectivity significantly.
The thesis is organized as follows:
In chapter 2, protein structures in four levels are briefly introduced and then kinase
structure is specifically described. In the following section, several relevant molecular at-
tributes of protein are discussed: First, we formally define a region, the nonpolar hull,
enabling comparison of targeted exposed nonpolar regions across different kinases. Sub-
sequently, we investigate the dehydration propensity of protein surface. A means is intro-
duced to calculate dehydration propensities on polar-paired regions on the protein surface.
Based on the concept of dehydration propensity, the so-called solvent-accessible hydrogen
bond, or dehydron, is defined. In order to expand our work to the kinases not reported in the
PDB database, we introduce a sequence-based means to calculate the dehydration propen-
sities by inferring from the disorder score (Braken et al., 2004), an accurate sequence-based
attribute that indicates the propensity of a chain window to be structurally disordered. At
last, another type of region, the environmental hull, is defined in order to compare polar
dehydration propensities across targets.
In Chapter 3, we first determine the type of molecular similarity that promotes promis-
cuity whenever targeted. Specifically, we demonstrate that solvent-exposed nonpolar re-
gions engaged in ligand association foster promiscuity. Then, we examine other targeted
features in molecular design aimed at inducing pair-wise interactions between ligand and
5kinase and show that the high degree of conservation of the partner groups on the pro-
tein surface does not enable a cogent control of specificity. Subsequently, we demonstrate
that the dehydration propensities is responsible for controlling specificity. To carry out the
analysis at a sequence level, we adopt the environmental alignment technique introduced
in Chapter 2, which enables the identification of residues whose microenvironment are
likely to be perturbed by ligand association. Such residues are identified by aligning the ki-
nase sequence against a background of sequences of homologous kinase-ligand complexes
reported in the PDB.
In Chapter 4, we discuss the first application of the structural marker governing speci-
ficity, i.e., the in silico drug profile predictor. To construct this drug profile predictor, we
first show how the profile prediction problem is re-cast in linear algebra terms. We then
solve the corresponding linear algebra problem. To carry out the prediction in practical
cases, some optimizing steps are needed, which is addressed in this chapter. To validate
the predictor, we test the predictions versus published experimental data with testing results
presented in this thesis. Also, we assess the performance of our predictor by comparing it
with other computational predictors.
Chapter 5 presents another application of the structural marker, that is, the strategy
to clean promiscuous inhibitors by introducing “wrapping” chemical modifications that
preserve the drug chemotype, while targeting unique dehydrons. First, we discuss the
possibility of cleaning cross-reactive drugs by exploiting the structural marker as selectivity
filters. Then we analyze the molecular basis of imatinib-redesigning to curb its potential
cardiotoxicity and further propose the general strategy of cleaning promiscuous inhibitors.
To illustrate the operational value of this approach, we focus on redesigning a promiscuous
6drug, EKB-569, to enhance its selectivety significantly. In details, we describe how to
trace the specific molecular basis for EKB-569 promiscuity, the modifications to remove
such sources of promiscuity and the modification to promote selectivity through targeting
a non-conserved dehydron.
Chapter 2
Protein Structure and Relevant
Molecular Attributes
2.1 Protein Structure
Proteins are large organic compounds made of amino acids arranged in a linear chain
and joined together by peptide bonds between the carboxyl and amino groups of adjacent
amino acid residues. They function as catalysts, transporters and store places of other
molecules such as oxygen, mechanical supporter, immune protector, and growth and dif-
ferentiation controller. Protein structure can be described at four levels: The primary struc-
ture refers to the amino acid sequence. The secondary structure refers to the conformation
adopted by local regions of the polypeptide chain. Tertiary structure describes the overall
folding of the polypeptide chain. Finally, quaternary structure refers to the specific asso-
ciation of multiple polypeptide chains to form multisubunit complexes. In this section we
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8only briefly describe the protein structures. More detailed information of this is available
in any textbook of biochemistry, e.g. Berg et al. (2002); Nelson and Cox (2005).
2.1.1 Amino acid and nonpolar group
Proteins are linear polymers of amino acids, each of which consists of a central tetra-
hedral carbon atom linked to an amino group, a carboxylic acid group, a distinctive side
chain, and a hydrogen atom (figure 2.1). All natural proteins are constructed from the
same set of 20 amino acids (table 2.1). The side chains of these 20 building blocks vary
tremendously in size, shape, the presence of functional groups and polarity. According to
side chain polarity, amino acids can be categorized as polar or nonpolar (cf. table 2.2).
Generally, polar side chains are hydrophilic while nonpolar side chains are hydrophobic.
Figure 2.1: The general structure of an amino acid, with the central α carbon atom in the
middle, the amino group on the left, the carboxylic group on the right, the side chain on
the bottom (R) and the hydrogen atom on the top.
9Table 2.1: The 20 amino acids
Glycine Alanine Valine Leucine
Isoleucine Methionine Proline
Phenylalanine Tyrosine Tryptophan
10
Serine Threonine Cysteine
Lysine Arginine Histidine
Aspartate Glutamate Asparagine Glutamine
One of the essential features of amino acids is the nonpolar groups within the molecules.
Nonpolar groups are defined as the carbonaceous groups that are within protein side chains
and are not directly connected to any polar groups (O, N, S). The nonpolar groups of all
the 20 amino acids are listed in table 2.2. In this table, each nonpolar group is represented
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by the C atom within the group, which is named following the naming rules used in PDB
database1. Note that some polar amino acids, e.g. lysine and arginine, do have nonpolar
groups within their side chains. On the other hand, glycine, which is nonpolar, does not
have any nonpolar group since its side chain is too small, only a hydrogen atom. However,
generally a nonpolar amino acid has more nonpolar groups than a polar amino acid does,
which is intuitive. The nonpolar groups constitute the atomic basis of our work because
they are able to wrap the hydrogen bonds between main chain atoms and thus protect the
wrapped hydrogen bonds from hydration. Notice that not only amino acids have nonpolar
groups, but ligands could also have them, that is, the carbonaceous groups within ligand
molecules not directly connected to any polar groups. Thus, ligands, e.g. drug molecules,
may also be able to wrap hydrogen bonds between main chain atoms when they properly
bind to proteins.
2.1.2 Protein structures in four levels
Amino acids are linked by peptide bonds to form polypeptide chains. The linkage is
formed by amide bonds between the carboxyl group of one amino acid and the amino group
of the next. This linkage, i.e. the so-called peptide bond, has several important properties.
First, it is resistant to hydrolysis so that proteins are remarkably stable kinetically. Second,
the peptide group is planar because the C-N bond has considerable double-bond character.
Third, each peptide bond has both a hydrogen bond donor (the NH group) and a hydrogen
bond acceptor (the CO group). Hydrogen bonding between these backbone groups is a
distinctive feature of protein structure. Lastly, the peptide bond is uncharged, which allows
1http://www.wwpdb.org/docs.html
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Table 2.2: Side chain polarities and nonpolar groups of all the 20 amino acids†
Amino Acid Side chain polarity nonpolar group
Glycine nonpolar
Alanine nonpolar CB
Valine nonpolar CB, CG1, CG2
Leucine nonpolar CB, CG, CD1, CD2
IsoLeucine nonpolar CB, CG1, CG2, CD1
Methionine nonpolar CB
Proline nonpolar CB, CG
Phenylalanine nonpolar CB, CG, CD1, CD2, CE1, CE2, CZ
Tyrosine nonpolar CB, CG, CD1, CD2, CE1, CE2
Tryptophan nonpolar CB, CG, CD2, CE3, CZ3, CZ2, CH2
Serine polar
Threonine polar CG2
Cysteine polar
Asparagine polar CB
Glutamine polar CB, CG
Aspartate polar CB
Glutamate polar CB, CG
Lysine polar CB, CG, CD
Arginine polar CB, CG
Histidine polar CB
† Nonpolar groups are represented by the C atoms within them,which are named following the naming rules
of PDB: CA (A representing α) is α-C in the main chain; CB (B representing β ) is β -C which is the C atom
closest to CA; CG is γ-C and so on. When there are two or more symmetric C atoms, they are denoted by
numbers, e.g. CD1 and CD2 are two δ -C’s. The convention using greak letters to identify carbons is
described in page 76 of Nelson and Cox (2005).
proteins to form tightly packed globular structures having significant amounts of the back-
bone buried within the protein interior. Because they are linear polymers, proteins can be
described as sequences of amino acids. Such sequences are written from the amino to the
carboxyl terminus.
Once the amino acids are linked into polypeptide chains, the chains can then fold into
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secondary structures, such as α helices, β sheets, and turns and loops. α-helix and β sheet
are the two major elements of protein’s secondary structure. In an α helix, the polypeptide
chain twists into a tightly packed rod, within which the CO group of each amino acid is
hydrogen bonded to the NH group of the amino acid four residues along the polypeptide
chain. In a β strand, the polypeptide chain is nearly fully extended. Two or more β strands
connected by NH-to-CO hydrogen bonds come together to form β sheets. Turns and loops
are usually the parts between α helices or β sheets and are generally more flexible than the
latter two.
Based on the secondary structures, proteins form their tertiary structures by folding into
compact globular shapes. The tertiary structures of water-soluble proteins have features as
follows: a) an interior formed of amino acid with hydrophobic side chains and b) a surface
formed largely of hydrophilic amino acids that interact with the aqueous environment. The
driving force for the formation of the tertiary structure of water-soluble proteins is the
hydrophobic interactions between the interior residues.
Furthermore, polypeptide chains can assemble into multisubunit structures, i.e. quater-
nary structures. Quaternary structure can be as simple as two identical subunits (i.e. dimer)
or as complex as dozen of different subunits. In most cases, the subunits are held together
by noncovalent bonds.
2.1.3 Protein kinase structure
In this thesis, we focus on one special type of protein: protein kinase. Protein kinases
are quintessential signal transducers, and thus their inhibition becomes a central strategy
to block specific signaling pathways, as often needed for therapeutic reasons (Taylor and
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Radzio-Andzelm, 1997; Donato and Talpaz, 2000; Dancey and Sausville, 2003; Fabbro and
Garcia-Echeverria, 2002; Gabriele and King, 2001; Myers et al., 1997). In fact, a number
of diseases, including cancer, diabetes, and inflammation, are linked to perturbation of
protein kinase-mediated cell signaling pathways (Noble et al., 2004). The human genome
encodes 518 protein kinases (Manning et al., 2002) that share a catalytic domain conserved
in structure but which are notably different in how their catalysis is regulated. The catalytic
domain of protein kinase is the main focus of this thesis. One typical catalytic domain of a
protein kinase (figure 2.2) consists of two lobes (N-terminal lobe and C-terminal lobe) and
the hinge part. The N-terminal lobe consists of a β sheet and one conserved α helix (helix
C). The C-terminal lobe is largely helical. The hinge region connects two lobes, through
the so-called catalytic loop or C-loop. C-loop, together with the activation loop (A-loop)
from the C-terminal lobe and the phosphorylation loop (P-loop) from the N-terminal lobe,
forms the ATP-binding site, which is also the binding site of ligand.
From a structural perspective, the kinase ATP pockets (Huse and Kuriyan, 2002; Noble
et al., 2004) are obvious targetable features. However, due to the common evolutionary
ancestry of kinases, ATP-binding sites are highly conserved in shape and amino acid com-
position across the superfamily (see the illustrative example in figure 2.3), making it hard
to achieve selectivity or control the inhibitory impact (Hopkins et al., 2006; Feng et al.,
2005). Thus, selectivity becomes a major challenge in kinase-inhibitor development. And
this is exactly the problem dealt with in this thesis.
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Figure 2.2: The structure of the catalytic domain of EGFR (1M17.pdb rendered by VMD).
It consists of two lobes (N-terminal lobe on the top and C-terminal lobe on the bottom)
and the hinge region (in red color). The N-terminal lobe consists of a β sheet and one
conserved α helix (helix C). The C-terminal lobe is largely helical. The hinge region
connects two lobes, through the so-called catalytic loop or C-loop (shown in red). C-loop,
together with the activation loop (or A-loop, indicated in yellow) from the C-terminal lobe
and the phosphorylation loop (or P-loop, indicated in blue) from the N-terminal lobe, forms
the ATP-binding site, which is also ligand-binding site.
2.2 Molecular attributes of protein
In this section we introduce a series of molecular attributes of protein in preparation for
the discussion in the next chapter.
2.2.1 Nonpolar hull
One important feature of protein is its polar/nonpolar pattern, i.e. the spatial distribu-
tion of polar amino acids and nonpolar amino acids within the protein. In order to assess
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Figure 2.3: Structural alignment of FAK (focal adhesion kinase, pdb code 2ETM),
a major cancer drug target, and INSR (insulin receptor kinase, pdb code 1GAG),
a target to be avoided at any cost in molecular therapy. The two structures
are aligned by DaliLite (http://www.ebi.ac.uk/DaliLite/) and rendered with VMD
(http://www.ks.uiuc.edu/Research/vmd/). Only backbones are indicated for clarity. The
structure similarity (RMSD∼ 0.9 Å) between the two kinases may lead to life-threatening
cross reactivity since INSR is indispensable kinase mediating the metabolic functions of
insulin.
differences in the nonpolar patterns of the exposed regions of kinase targets that interact
with different ligands, we first define a common region, named the nonpolar hull. A residue
a is defined as making contact with a ligand L within a PDB-reported complex if a side-
chain heavy atom (H excluded) is found to be within 3.6 Å (upper bound for any bond
length) of a heavy atom in the ligand. The nonpolar hull for protein chain i, Hnp(i), is de-
pendent on a ‘structural background set’ of chains, S(i), which includes all homolog chains
that align with chain i (Higgins et al., 1996) for which there are protein-ligand complexes
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with reported structure. Thus, the nonpolar hull is defined as
Hnp(i) = ∪ j∈S(i)Φi(Rnp( j)), (2.1)
where Φ is the alignment operator such that Φi(a), with a ∈ chain j, is the residue in chain
i that aligns with residue a in chain j, and Rnp( j) is the set of nonpolar residues (cf. table
2.2) in chain j in contact with its respective ligand L j. For any pair i, j, the following
property holds:
Φi(Hnp( j)) = Hnp(i), (2.2)
which enables a comparison of kinases by examining differences in nonpolar hulls. Figure
2.4 illustrates the definition of nonpolar hull and 2.5 shows an example: the nonpolar hull
of the active fold of pregnane X receptor (PXR).
2.2.2 Hydration environment and dehydration propensity of hydro-
gen bond
Now we introduce another molecular attribute of protein, i.e., the hydration microen-
vironment of hydrogen bonds in protein. A preformed hydrogen bond microenvironment
may be determined from the atomic coordinates of the protein by calculating the extent
of intramolecular dehydration, ρ , quantified as the number of the side chain carbonaceous
nonpolar groups (cf. table 2.2) within a dehydration domain (cf. figure 2.6). This domain
consists of two intersecting balls of radius 6.0 Å (∼ width of three solvation layers (Fer-
nández and Berry, 2004)) centered at the α-carbons of the hydrogen-bond paired residues.
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Figure 2.4: Nonpolar hull. Each grid represents a redidue and each grid chain represents a
protein chain. The chains are aligned with each others. The yellow grids are the nonpolar
residues and the nonpolar hull is colored in red.
In soluble protein domains, at least two thirds of the backbone hydrogen bonds lie in the
range ρ = 26.6±7.5. A subsequent concept based on the dehydration propensity is solvent-
accessible hydrogen bond (SAHB), or sometimes named as dehydron. In the following part
of this thesis, both of the two names will be used. SAHB is defined such that the extent
of intramolecular dehydration (ρ) of a solvent-accessible hydrogen bond lies in the tails
of the distribution, i.e., with 19 or fewer nonpolar groups in its microenvironment. That
is, its ρ-value is below the mean, minus one Gaussian dispersion. Such bonds constitute
dehydration-propensity hot spots as demonstrated before (Fernández, 2004; Fernández and
Berry, 2004).
The SAHBs may be determined directly from a PDB file using the program YAPView2.
2YAPView is developed in a CS lab of University of Chicago and can be downloaded from website:
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Figure 2.5: The nonpolar hull of the active fold of pregnane X receptor (PXR) in complex
with SR12813 (PDB.1ILH). The virtual bonds between α-carbons are depicted in blue,
while the residues in the hull are shown in yellow.
This program is inspired in earlier desolvation calculations (Fernández et al., 2002). Within
YAPview, the SAHBs are identified by loading the PDB file, choosing a structure dis-
play/representation and enabling a desolvation calculation. The latter is needed to deter-
mine the extent of intramolecular dehydration of hydrogen bonds. This operation requires
the selection: Configuration→ General Options→ Desolvation. Thereafter, one needs to
enable the desolvation calculator and select the appropriate parameters, especially desol-
vation radius and desolvation threshold, according to the indications given above.
Thus, YAPView displays the dehydration-propensity hot spots directly on the protein
surface: The hydrogen bonds that are poorly dehydrated intramolecularly, that is, below
http://sourceforge.net/project/showfiles.php?group_id=133896&package_id=225002
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Figure 2.6: Hydrogen-bond microenvironment. Intramolecular dehydration, ρ , is quan-
tified as the number (16 in this case) of side-chain nonpolar groups (black disks) within
the dehydration domain (the two intersecting spheres) defining the microenvironment of a
particular hydrogen bond.
the pre-selected threshold are shown in green in the structure display and promote the
exclusion of surrounding water.
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2.2.3 Sequence-based prediction of dehydration propensity
While YAPview can directly calculate the hydration propensities of hydrogen bonds
and thus identify SAHBs from PDB file, our analysis is not constrained to PDB-reported
kinases. Robetta/Rosetta predictions of active structures (Bonneau et al., 2002; Chivian
et al., 2005) become reliable given the extent of PDB representation ( 27%) of paralogs
within the kinase superfamily and since SAHBs may be directly inferred from sequence
(Fernández and Berry, 2004), and contrasted with the structure predictions for mutual val-
idation. Such SAHB inferences make use of a strong correlation between the extent of
dehydration of the preformed hydrogen bonds and the disorder score (Braken et al., 2004),
an accurate sequence-based attribute that indicates the propensity of a chain window to
be structurally disordered. The correlation is maintained irrespectively of whether the
structure is a Rosetta prediction or PDB reported and implies that native disorder arises
essentially from the impossibility to dehydrate intramolecular hydrogen bonds. Figure 2.7
illustrates the strong correlation.
The disorder propensity is given by a score determined by the program PONDR®(Braken
et al., 2004), a neural-network predictor of native disorder. Only 0.4% of more than 900
non-homologous PDB proteins give false positive predictions in regions with 40 or more
consecutive sites of predicted disorder. Even this 0.4% of false positives is an overestima-
tion, as many disordered regions in monomeric chains become ordered upon ligand binding
or in crystal contacts (Braken et al., 2004). The false negatives error rate ( 11% for regions
of 40 or more consecutive predicted ordered residues) is also compelling in regards to the
predictor quality.
The correlation between solvent exposure of hydrogen bonds and disorder propensity
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Figure 2.7: Correlation between the disorder score of a residue and the extent of in-
tramolecular dehydration (ρ) of the backbone hydrogen bond engaging that particular
residue. The disorder score on each individual residue was obtained for 2806 nonredundant
nonhomologous PDB domains. Residues have been independently grouped in 46 bins of
400 residues each, according to the extent of wrapping (7≤ ρ ≤ 52). The average score has
been determined for each bin, and the error bars represent the dispersion of disorder scores
within each bin. The strong correlation between the disorder score and extent of wrapping
and the dispersions obtained imply that dehydrons can be safely inferred in regions where
the disorder score is above 0.35.
implies that it is possible to predict SAHBs directly from sequence (Fernández and Berry,
2004): It suffices to determine the PONDR-generated pattern associated with the desired
feature. The correlation implies that the propensity to adopt a natively disordered state
becomes pronounced for proteins which, due to a chain composition reflecting high hy-
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drophilicity, cannot protect even minimally the backbone hydrogen bonds. Thus, we can
infer the existence of SAHBs from the PONDR score (λd) with 92% accuracy in regions
with λd >0.35 provided such regions are flanked by well-protected regions (λd < 0.35), to
ensure the existence of structure. The accuracy of this sequence-based SAHB predictor
was established by inferring the location of SAHBs in proteins with reported structure, for
which the microenvironment of each hydrogen bond can be determined unambiguously
(Fernández and Berry, 2004). The false negatives constitute 368 of the 8,215 SAHBs
in a PDB database of 1,466 proteins free from structural redundancy and less than 25%
sequence identity in pairwise alignment. The false positives correspond to 2721 of the
133,623 backbone hydrogen bonds examined.
2.2.4 Environmental hull and environmental alignment technique
To assess differences in the dehydration propensities of polar regions for purported
kinase targets, we introduce a common region named environmental hull, which is defined
in a way similar to that of nonpolar hull (section 2.2.1). First, the set Renv( j) is defined for
protein chain j as the set of residues paired by SAHBs in chain j within a protein-ligand
complex with reported structure subject to the following condition: ligand L j contributes
to the dehydration of the SAHB, that is, it has some carbonaceous nonpolar groups within
the dehydration domain of the SAHB. Then, the set Eenv( j) is defined as the set of residues
from chain j that contribute to the dehydration microenvironment of a SAHB contained in
Renv( j), that is, they are either paired by the SAHB or they contain a side-chain nonpolar
group within the microenvironment of the SAHB. Then, the environmental hull for chain
j, Henv( j), is defined as the union of the residues in chain j that align with residues framing
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the environments of SAHBs that in turn are environmentally affected by ligands in PDB-
reported complexes:
Henv( j) = ∪i∈S( j)Φ j(Eenv(i)) (2.3)
where notation has been followed consistently and the structural background S(j) is defined
above. As with nonpolar hulls, for any pair i, j, the following property also holds:
Φi(Henv( j)) = Henv(i). (2.4)
As a property similar to that of nonpolar hull, the equality is needed to actually compare
environments of different proteins. Figure 2.8 illustrates the definition of enrironmental
hull and figure 2.9 shows a real example of this definition.
2.3 Summary
The main purpose of this chapter is to introduce the background knowledge for the
research presented in this thesis. We first briefly introduced protein structures in four levels,
and specifically, the kinase domain of kinase proteins, which is the central object of our
research.
In preparation for the following investigations, several relevant molecular attributes of
protein have been defined and described. First, we formally defined a region, the nonpolar
hull, enabling comparison of targeted exposed nonpolar regions across different kinases.
Subsequently, we investigate the dehydration propensity of protein surface. A means is
introduced to calculate dehydration propensities on polar-paired regions on the protein
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Figure 2.8: Environmental hull. Each grid represents a redidue and each grid chain repre-
sents a protein chain. The chains are aligned with each others. The green grids represent
the residues forming dehydons (SAHBs) while the yellow grids represent the residues con-
taining side-chain nonpolar group within the microenvironment of any dehydron. The
environmental hull is colored in red.
surface. Based on the concept of dehydration propensity, the so-called solvent-accessible
hydrogen bond, or dehydron, is defined. This is the most important molecular basis for the
researches presented in the following chapters.In order to expand our work to the kinases
not reported in the PDB database, we introduce a sequence-based means to calculate the
dehydration propensities by inferring from the disorder score (Braken et al., 2004), an
accurate sequence-based attribute that indicates the propensity of a chain window to be
structurally disordered. At last, another type of region within protein, the environmental
hull, is defined in order to compare polar dehydration propensities across targets.
All the following chapters are based on the background knowledge introduced in this
chapter. In Chapter 3, we investigate the relationships between the molecular attributes of
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Figure 2.9: Aligned backbones for PDK1 (blue) in complex with BIM8 (PDB.1UVR) and
CHK1 (lilac) in complex with 3A3 (PDB.2CGU), with the environmental hulls depicted in
light blue.
kinase proteins and drugs’ affinity profiles against kinase proteins and identify the molec-
ular basis for the specificity of kinase inhibitor. In Chapter 4, the dehydron concept is
further exploited to infer the pharmacological differences between kinases and thus to pre-
dict affinity profiles of drug. In Chapter 5, the dehydron is adopted as a structural marker
for the manipulation of therapeutic impact in drug design/redesign.
Chapter 3
Molecular Basis for Promiscuity and
Specificity
The elucidation of the molecular factors governing promiscuity and specificity in molec-
ularly targeted drug therapy requires that we attempt to correlate different molecular at-
tributes with available screening data for a sizable set of kinase targets. In this chapter we
first reveal the molecular basis for promiscuity: pair-wise interactions between ligand and
kinase target corresponding to the high conservation of the partner groups on or around the
ATP-binding site of the kinase. Subsequently, we show that the SAHB defined in Chapter
2 may be targeted to promote specificity. The large assayed set adopted (Fabian et al.,
2005) is highly underreported in the PDB and consequently, a reliable sequence-based
predictor (see section 2.2.3) of the relevant molecular attributes had to be implemented.
We adopted Robetta/Rosetta predictor (Bonneau et al., 2002; Chivian et al., 2005) to ac-
complish the sequence-based predictions wherever needed and validated the results with
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disorder propensity (Braken et al., 2004). The predictor is based on alignments against
sequences of PDB-reported kinases that are used to define the windows for comparison.
3.1 Molecular basis for promiscuity
3.1.1 Pharmacological distance
In order to elucidate the relationship between compounds’ molecular attributes and
their affinity profile for the kinases, we first define a pharmacological distance, dphar, that
quantifies differences in the affinity profiling of kinases against a background of available
drugs (Fabian et al., 2005). The idea behind this metric is that any factor governing the
specificity of kinase inhibitor should be able to construct a quantity that is correlated with
pharmacological distance. This metric is the Euclidean distance between affinity vectors
with entries given in negative logarithm of dissociation constant or ∆G/RT units (∆G =
free energy change for protein-ligand association, R = universal gas constant, T = abso-
lute temperature). The cutoff value for “no hit” affinities is ∆G/RT = ln10 ≈ 2.3 (i.e.
Kd,cuto f f = 10µM, Fabian et al., 2005). And every “no hit” entry (with Kd > Kd,cuto f f
)in the screening table of (Fabian et al., 2005) is assigned the value −23.026∆G/RT -unit,
corresponding to a large dissociation constant Kd = 1010µM. The distance is given by
dphar(i, j) =
[
∑
m∈drug background
(K(i,m)−K( j,m))2
]1/2
, (3.1)
where K(i,m), K( j,m) represent respectively the negative logarithm of equilibrium con-
stants for complexation of kinase i and kinase j with drug inhibitor m belonging to the
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drug background. Figure 3.1 displays the matrix Dphar = [dphar(i, j)] for all pairs (i, j)
from the 119 assayed kinases. Theoretically, the drug background should cover all the
existent drugs and thus the corresponding affinity vector space should have almost infinite
dimensions. However, this is not practically feasible because of two major reasons: 1)
An infinite-dimensional space cannot be handled numerically; 2) For some of the drugs,
we have no profile information at all and thus the corresponding dimensions are “invis-
ible”. Practically, we only adopted a number of drug compounds to constitute the drug
backgroun, which is in fact a subspace of the complete drug background. The affinity pro-
filing adopted included 19 of the 20 drugs originally screened (Fabian et al., 2005): only
the promiscuous ligand staurosporine was initially excluded since it does not belong to the
pharmacology realm.
3.1.2 Nonpolar pattern and promiscuity
To determine whether pharmacological differences are dictated by differences in non-
polar accessible surfaces of the targets within ligand-binding sites, a nonpolar distance,
dnp(i, j), between the affinity-assayed kinases i, j is introduced. The dnp(i, j) is determined
by differences in accessible nonpolar surface areas of the respective nonpolar hulls, Hnp(i),
Hnp( j). The nonpolar hull of a kinase (section 2.2.1) is comprised of the nonpolar residues
of the kinase in contact with its drug ligands, whenever the complexes are reported in PDB,
and residues in the kinase (not necessarily nonpolar) that align with nonpolar residues in
contact with ligands in PDB-reported ligand-kinase complexes (Figure 3.2). Introducing
the hull becomes necessary to compare kinases at this level. Thus, the nonpolar distance is
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Figure 3.1: Pharmacological distance matrix Dphar = [dphar(i, j)] for all pairs (i, j) from
the 119 kinases assayed through affinity profiling against a background of 19 drugs (Fabian
et al., 2005):SB202190; SB203580; sp600125; imatinib (Gleevec); VX-745; BIRB 796;
BAY-43-9006; GW-2016; gefitinib; erlotinib; CI-1033; EKB-569; ZD-6474; Vatalanib;
SU11248; MLN-518; LY-333531; roscovitine/CYC202 and flavopiridol.
expressed as
dnp(i, j) =
1
[A(Hnp(i))]
∑
a∈Hnp(i)
|P(a)−P(Φ j(a))|, (3.2)
where
A = nonpolar accessible area ((Fraczkiewicz and Braun, 1998);
a = generic residue in chain i;
P(a) = 0 if a is polar, 1 if a is nonpolar;
Φ j(a) = residue in chain j that aligns with a in i.
31
Figure 3.2: Aligned backbones(Hogue, 1997) (RMSD≈ 0.33 Å) for paralog kinases PDK1
(blue) and CHK1 (lilac) in their active folds. The structures were reported in complex with
ligands BIM8 (PDB.1UVR) and 3A3 (PDB.2GCU), respectively. The nonpolar hulls are
depicted in yellow, and were computed taking into account only the two PDB complexes.
Only 32 of the 119 assayed kinases are reported in PDB complexes (Fernández and
Maddipati, 2006), yet, structural inferences can be made with confidence ((Bonneau et al.,
2002; Chivian et al., 2005; Fernández and Berry, 2004) given the kinase homology ((Man-
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ning et al., 2002) and high alignment (RMSD <0.9 Å) across reported structures (Fernández
and Maddipati, 2006). The prediction accuracy decreases somewhat but in a quantifiable
manner (∼ 12%) on loopy regions (section 2.2.3). The matrixDnp = [dnp(i, j)] (Figure 3.3)
Figure 3.3: Nonpolar distance matrix Dnp = [dnp(i, j)] over the 119 assayed kinases. The
numerals in rows and columns follow Figure 3.1
reveals remarkable nonpolar similarity across kinases: < dnp > /(max(dnp))≈ 11% (<> =
average over kinase pairs); < [dnp− < dnp >]2 >
1
2 / < dnp >≈ 16%. This similarity im-
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plies a high conservation of accessible nonpolar surface, an indication that ligands whose
affinity is dominated by hydrophobic interactions should be highly promiscuous.
The plot dnp vs dphar for all (119× 118)/2 kinase pairs (i, j) shows no correlation
between the two metrics (Figure 3.4). This suggest that nonpolar pattern should not be
Figure 3.4: Plot of nonpolar distance versus pharmacological distance. Each circle rep-
resents a kinase pair. No correlation is observed, while there is some bimodality in each
dimension.
the molecular basis for kinase inhibitor. However, when the highly promiscuous affinity-
dominant staurosporine is incorporated to the affinity profile (Fabian et al., 2005) and the
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affinity-based distance matrix is recalculated (dphar → dps = pseudopharmacological dis-
tance), a good correlation (R2 = 0.875) between dps and dnp is obtained (Figure 3.5). This
Figure 3.5: correlation between pseudopharmacological distance (including staurosporine
in the drug screening background) and nonpolar distance between kinases. The sole out-
liers are pairs involving the EGFR kinase, the kinase whose affinity vector is not dominated
by staurosporine (cf. Fabian et al. (2005), Figure 5).
correlation reveals that promiscuity, the dominant affinity trait when staurosporine is incor-
porated, is fostered by targeting accessible nonpolar moieties, in turn, a highly conserved
feature of protein interfaces (Ma et al., 2003). The strong correlation shown in figure 3.5
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implies that staurosporine should bind mainly through hydrophobic contacts, as it is indeed
the case in its PDB complexes (Fernández and Maddipati, 2006).
Significantly, the most promiscuous drug target, the pregnane X nuclear receptor (PXR,
PDB accession code 1ILH), believed to bind to over 50% of human drugs (Hopkins et al.,
2006) contains the most extensive nonpolar hull per 1000 Å2 of ligand surface of all com-
plexes reported in PDB (Figure 3.6), and the highest density of nonpolar accessible surface:
660 Å2 per 1000 Å2 of accessible surface within the nonpolar hull.
Figure 3.6: The nonpolar hull of the active fold of pregnane X receptor (PXR) in complex
with SR12813 (PDB.1ILH). The virtual bonds between α-carbons are depicted in blue,
while the residues in the hull are shown in yellow.
On the other hand, sequence alignment including the 32 assayed kinases with PDB-
reported complexes (Fernández and Maddipati, 2006) reveals that residues in ATP-binding
sites engaged in hydrogen bonding with ligands are highly conserved, with 0≤σ(n)≤ 0.21
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(n = chain position for hydrogen-bonding residue; σ= information entropy reflecting amino
acid variability after sequence alignment); average σ in Hnp = 0.87; max(σ) = ln20≈ 4.2
(Higgins et al., 1996; Shenkin et al., 1991). As expected, differences in hydrogen-bonding
capabilities do not appreciably correlate with dps (R2 ≈ 0.19), and there is no correlation
with dphar.
3.2 Molecular basis for specificity
These observations discussed in the previous section lead to the question: What feature
may be targeted to promote specificity? We need to identify a feature with sufficient vari-
ability across homologs and capable of influencing the affinity for the ligands by modulat-
ing the local propensity for water exclusion. Thus, we focus on “environmental residues”,
i.e. those residues framing the microenvironment of intramolecular solvent-accessible
backbone hydrogen bonds (SAHBs) (Fernández and Berry, 2004). These bonds may be-
come intermolecularly dehydrated upon ligand association. They promote such associ-
ations because the enhancement and stabilization of electrostatic interactions overcomes
the thermodynamic cost associated with removing the surrounding water molecules that
hydrate amide or carbonyl groups (Fernández and Berry, 2004). Environmental residues
include the hydrogen-bonded residues themselves. To compare environments of different
kinases, we define the environmental hull of a kinase, Henv, as the reunion of all environ-
mental residues in the chain and residues aligning with environmental residues from other
chains (figure 3.7, see section 2.2.4 for details). Thus, an environmental distance denv(i, j)
between kinases i and j is obtained by comparing the aligned hydrogen-bond microenvi-
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Figure 3.7: Environmental hull (light blue) for CHK1 (obtained from alignment with
PDK1). Solvent-accessible hydrogen bonds (SAHBs) are indicated as green segments join-
ing the α-carbons of the paired residues. The virtual bonds are shown as blue segments.
The three SAHBs perturbed by the ligand (3A3) are C87-G90; G90-L138; G16-V23.
ronments within Henv(i) and Henv( j):
denv(i, j) =
1
M(i, j) ∑
n=1,...,M(i, j)
∆n(i, j), (3.3)
where M(i, j) = number of residue pairs in Henv(i) corresponding to SAHBs in kinase i or to
hydrogen bonds or nonbonded residue pairs that align with SAHBs in Henv( j); n = dummy
index denoting residue pair, and ∆n(i, j) = 1 if residue pair n corresponds to a SAHB in
Henv(i) that aligns with a non-SAHB in Henv( j) or vice versa, and ∆n(i, j) = 0, otherwise.
Thus defined, the environmental distance compares local dehydration propensities associ-
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ated with SAHB patterns in kinases. The validity of the relation: Φi(Henv( j)) = Henv(i)
enables a rigorous comparison between environments of two different proteins, in contrast
with earlier attempts (Fernández and Maddipati, 2006).
Figure 3.8: Environmental distance matrix Denv = [denv(i, j)] for the 119 kinases assayed
(Fabian et al., 2005).
The matrix Denv = [denv(i, j)] for the 119 kinases assayed (Fabian et al., 2005) (figure
3.8) is obtained after inference of the SAHBs for the 87 kinases unreported in PDB from
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direct structure prediction (Bonneau et al., 2002; Chivian et al., 2005). The predictions are
validated through a correlation with an independent and accurate sequence-based predic-
tion of another structural attribute: the disorder propensity (Braken et al., 2004; Fernández
and Berry, 2004). This attribute was chosen because loopy regions, in the twilight between
order and disorder, compromise somewhat the accuracy of a structure prediction. The val-
idation is based on the fact that the extent of intramolecular hydration of a hydrogen bond
correlates strongly with the disorder propensity: disorder arises from an impossibility to
sufficiently hinder hydration of amides and carbonyls (Fernández and Berry, 2004) (see
section 2.2.3 for details). The strong correlation between denv and dphar (R2 ≈ 0.917) (Fig-
ure 3.9) reveals that the impact of drugs on the human kinome is dictated by differences
in hydration microenvironments across the ligand-binding regions of the kinases. To the
best of our knowledge, the hydration differences across kinases, quantified through the
metric denv, were not considered in the development of the drugs screened in Fabian et al.
(2005). The diversity in hydration microenvironments needed to yield specificity across
paralog kinases results from the variability (< σ >≈ 1.38) of environmental residues, while
< σ >≈ 0.21 when the average is restricted to residues paired by hydrogen bonds that are
environmentally affected by the ligands.
The metric denv is defined at the sequence level by identifying the comparison win-
dow through environmental alignment (section 2.2.4). This technique required aligning
residues with those in homolog kinases with reported structure whose microenvironments
are known to be affected by ligand association. Thus, in contrast with the structure-based
packing distance that compares SAHBs wrapped by ligands in the structures of two com-
plexes (Fernández and Maddipati, 2006), a background of homologs, S, is needed to com-
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Figure 3.9: Correlation of environmental versus pharmacological distance. The line indi-
cates the optimal linear fit. The red diamonds correspond to the six pairs including ABL1,
the primary target for imatinib, and each of its six mutants, listed in Figure 3.1, that confer
different degrees of drug resistance.
pare sequence pairs using denv. If S is limited (cardinal <5), denv is well approximated by
dpack, but for a more extended and reliable window of comparison (determined by align-
ing the test sequence to more PDB-homologs), denv becomes a distinctive metric (Figure
3.10). This extended comparison is required to make reliable sequence-based inferences
and incorporates for a given protein the alternative binding regions found in homologs.
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Figure 3.10: Relation between packing and environmental distance as function of the size,
#S, of the structural background set used to define the environmental hull. The 103 struc-
turally reported kinases were used for the analysis and their environmental distances were
computed as if the structure were unknown. For a reduced background (#S < 5), the pack-
ing metric is well approximated by denv, although with significant dispersion (∼ 25%, error
bars). As more structural background is included (#S > 4), packing distance becomes an
overestimation.
Local hydration differences determining specificity of drug inhibitors may arise in ki-
nase pairs with high degree of structural alignment (Hogue, 1997) (RMSD ≈ 0.3 Å), such
as SRC and LCK. The latter is a known target for Gleevec (imatinib), which may thus
act as immunosuppressant (Dietz et al., 2004), while SRC shows no affinity for the drug
(Fabian et al., 2005). Strikingly, two SAHBs in LCK, G254-G257 and R397-A400 that
promote their own dehydration through protein-imatinib association (figure 3.11), are ab-
sent from SRC: regions in the twilight zone between order and disorder in LCK become
fully disordered in SRC, as shown by the absence of electron density (figure 3.11). Thus,
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Figure 3.11: Environmental differences between the highly alignable native folds of LCK
(blue) and SRC (lilac). The two SAHBs G254-G257 and R397-A400 are present only in
LCK, a target for imatinib, while SRC has no affinity for the ligand.
while structurally similar, the environmental distance between SRC and LCK is sufficient
to account for the selective affinity of imatinib.
Drug-resistant mutations in another imatinib target, Bcr-ABL (ABL1), produce en-
vironmental differences that correlate approximately with the pharmacological distances
between mutant and wild type (red diamonds in figure 3.9). Upon close examination, the
most effective mutations (Fabian et al., 2005) T315I and E255K are precisely the ones that
have the most dramatic effect in increasing the dehydration (by adding nonpolar groups to
the microenvironment) of preformed SAHBs Q300-E316, and G251-G254, respectively.
These SAHBs are part of the environmental hull of wild-type Bcr-ABL. All reported ABL1
mutations actually perturb the dehydration propensity of SAHBs (figure 3.12). The poor-
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est correlation between environmental and pharmacological distance (figure 3.9) arises for
mutations E255K, H396P, likely to perturb affinity through other mechanisms that super-
sede environmental change. Overall, the drug-resistant mutations significantly decrease the
dehydration propensity of the target surface and accordingly decrease the inhibitor affinity.
Figure 3.12: Environmental impact of the drug-resistant mutations of ABL, a primary
target for imatinib (PDB.1IEP, ligand shown in complex). Only the side chains of the
mutating residues are indicated, together with the SAHBs (green) whose microenviron-
ments they affect. Hydrogen bonds not accessible to solvent are shown as thin segments
in light grey. The mutations with the SAHBs affected (in brackets) are: T315I (Q300-
E316); E255K (G251-G254); Q252H (L248-G251; G249-Q252; G251-G254); Y253F
(L248-G251; G249-Q252; G251-G254); M351T (E352-K356); H396P (H396-A399).
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3.3 Conclusion
In this chapter, we identified the molecular code for promiscuity and specificity in
targeting drugs that impact the human kinome. Thus, significant progress in the informat-
ics of drug design has been achieved by determining the type of similarity among targets
that promotes promiscuity and the type of difference that controls specificity. The for-
mer corresponds to highly conserved exposed nonpolar moieties in alignable regions of
protein-ligand interfaces, while the latter corresponds to nonconserved hot spots of high
dehydration propensity around amide-carbonyl pairs.
Kinase structures may be tightly aligned except in the regions of highest conformational
plasticity, precisely the regions of catalytic and regulatory relevance (Huse and Kuriyan,
2002). These loopy regions are obviously rich in packing defects, as their backbone hydro-
gen bonds are not fully buried and thus contain hot spots of dehydration propensity. Thus,
a way to achieve a classification of kinases is to assess differences in the nonconserved mi-
croenvironments of their loopy regions. As shown in this thesis, such microenvironmental
differences reflect the differences in binding affinity against a representative set of drugs.
The analysis was carried out at a genomic scale, since the environmental assessment of
local dehydration propensities can be reliably determined from sequence (c.f. Fernández
and Berry, 2004). The sequence-based predictor became operational because of the high
level of structural similarity reported for the kinase superfamily, combined with relatively
low sequence homology levels that enable target discrimination. These properties paved
the way to the mapping of a reliable sequence-based attribute, the disorder propensity, onto
a molecular feature, the dehydration propensity, shown to be effectively sculpted in drug
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ligands to modulate specificity.
In future work, our methodology will be adapted to model specificity control in drug-
targeted nuclear hormone receptors. The moderate structure conservation of the ligand-
binding domain (Escriva et al., 2000) and the significant PDB representation needed to
construct a reliable structural background instills confidence in the success of our environ-
mental predictor.
The problem in this chapter is essentially handled by calculating pharmacological dis-
tances (distances between vectors) from affinity profiles (vectors). However, in practical
work it is the affinity profiles that drug developers are finally concerned with. This leads
us to the inverse problem of determining affinity profiles of individual kinases from their
predicted pharmacological distances. This problem will be investigated in next chapter.
Chapter 4
In silico drug profiling of the human
kinome
In Chapter 3 we identified the molecular basis for drug promiscuity and specificity. In
this chapter we introduce an application of this discovery of the structural marker governing
specificity. This application is to solve one of the major problems in drug development, i.e.,
the screening of drug profile against a large protein library. Let’s start with a brief review
regarding the background of the problem: affinity-profile screening in drug development.
A primary problem in drug development, to identify compounds with controlled speci-
ficity against clinically relevant targets, is usually handled in early stages of development
by high-throughput screening, both experimentally and computationally (in silico)(Drews,
2000; Bleicher et al., 2003). Due to the increasing cost resulting from high clinical fail-
ure rates in a downstream stage of development, drug designers are prone to terminate
the efforts on those compounds likely to fail in late stages as early as possible(Bleicher
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et al., 2003). This “fail early” strategy places a significant responsibility on the early-stage
compound profiling(Liszewski, 2006). The two basic types of screening, experimental and
computational, are complementary approaches: the former is relatively accurate but cost-
limited by the size of the compound library to be profiled (Fabian et al., 2005), while the
latter is more time- and cost-efficient but less reliable(Bleicher et al., 2003; Kitchen et al.,
2004; Shoichet, 2004). In silico screening methods(Oprea andMatter, 2004) can be catego-
rized as either ligand-based(Lengauer et al., 2004) or target-based(Lyne, 2002). The latter
is becoming mainstream for cases where target structural information is available(Kitchen
et al., 2004; Oprea and Matter, 2004; Kuhn et al., 2002). Most of the target-based virtual
screening is performed by docking and scoring(Lyne, 2002). However, the inaccuracies
of scoring functions pose a major problem in target-based virtual screening(Kitchen et al.,
2004; Shoichet, 2004). Such docking-based algorithms are inadequate to examine kinase
targeting(Huse and Kuriyan, 2002; Mizutani and Itai, 2004; Mizutani et al., 2006; Chen
et al., 2007; Bain et al., 2003; Druker, 2004; Hopkins et al., 2006; Knight and Shokat,
2005; Vieth et al., 2004) because most of them do not take into account the induced fits
upon binding, which are crucial for kinase-ligand associations that typically involve loopy
regions(Huse and Kuriyan, 2002). There exist some docking-based algorithms that take
into account induced fits, but they still cannot handle extensive induced fit adaptation in-
cluding large movements of the backbone(Mizutani and Itai, 2004; Mizutani et al., 2006),
which is just the case for the loopy regions in kinases. In fact, kinase ATP-pockets are partly
framed by floppy regions, including the activation loop, catalytic loop and P-loop(Huse and
Kuriyan, 2002). These parts of the structure undergo an order-upon-binding transition upon
association with the ligands (natural or otherwise) which cannot be captured with a dock-
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ing algorithm, no matter how well it is able to handle flexibility. The induced fit problem
as it stands today is almost as hard as the protein folding problem and no algorithm deals
with it effectively from first principles.
This problem notwithstanding, the molecular markers for specificity and promiscuity
discussed in Chapter 3 may herald the advent of novel predictive tools for drug affinity pro-
filing by providing a new vantage point for kinase comparisons, as described in this chapter.
These comparisons will enable us to predict cross reactivities. Unexpected cross reactivi-
ties became recently apparent with the advent of high-throughput experimental screening
techniques(Fabian et al., 2005) based on bacteriophage kinase display. Thus, the affinity
profiles of 20 inhibitors against a battery of 119 kinases have been reported(Fabian et al.,
2005). However, the operational value of these assays to identify leads from within a com-
pound library ( 1000 compounds) is limited by cost, justifying our development of in silico
profiling tools.
In this chapter we introduce a predictive profiler based on the assumption that a structure-
based feature-similarity comparison of molecular targets can be used as a surrogate for the
differences in their pharmacological behavior. Our approach exploits the the discovery of
the structural marker governing specificity discussed in Chapter 3, a result holding even
for kinases lacking PDB representation and, based on this feature, it introduces a compari-
son of kinases including purported targets and experimentally confirmed targets. The core
of our affinity-profile predictor involves determining a linear propagator of profiling data.
This propagator consists of the structure-based estimation of pharmacological distances
across kinases. Once the propagator is computed, the inference of affinity profiles for test
drugs becomes a problem in distance geometry.
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4.1 Procedures of Drug Profiling
4.1.1 Operational premises of the predictor.
In Chapter 3, we introduced the environmental distance matrix (Denv) for all kinase
pairs obtained from the respective differences in the SAHB (i.e., dehydron) patterns within
aligned structures. On the other hand, the differences in the affinity profiles of kinases
against a background of drugs are quantified and arrayed in the so-called pharmacological
distance matrix Dphar. Furthermore in Chapter 3, we revealed a tight linear correlation
between the environmental and the pharmacological distances (c.f. Section 3.2), thus de-
lineating the molecular basis for cross reactivity. The profiling method presented in this
chapter is an application of this correlation to estimate Dphar from Denv and further, to
construct a full affinity profile for a test compound from its sub-profile obtained from ex-
perimental affinity assays against a small kinase subset. This problem becomes a linear
algebra problem, where the full affinity vector for a given drug may be determined from
suitably defined distances between kinases and the experimentally obtained affinity vector.
The implementation of the profiling method is thus carried out according to the follow-
ing steps (sketched in Figure 4.1 and Figure 4.2):
1. Estimate the pharmacological distance matrix (Dphar) defined over all kinase pairs
by appropriately rescaling the environmental distance matrix (Denv). This estimation
will increase in accuracy as a more comprehensive background of drugs, i. e. one
covering all kinase targets, is used to determine pharmacological behavior.
2. For every test compound to be fully profiled in silico, choose a subset of kinases to
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Figure 4.1: Flow chart (left) of the in silico profiling method.
obtain a small-scale experimental affinity profile, heretofore noted the “sub-profile”.
The required size of the kinase subset sampled to produce the sub-profile depends on
the fixed number of inhibitors that define the pharmacological matrix Dphar.
3. Determine the full affinity profile for a test compound from its sub-profile and our
estimated Dphar.
4. Repeat the steps above for each test compound in the library.
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Figure 4.2: Process diagram (right) of the in silico profiling method. Each column cor-
responds to one compound and each row to one kinase. The brown columns correspond
to the compounds with profiles already known and the red column corresponds to the test
compound. The upper rows represent the sub-profiles that are obtained from experiments
and the lower rows represent the profiles predicted by the profiler.
The sub-profile used as input information in Step 2 and Figure 4.1 and 4.2 is obtained
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from small-scale experiments, most advantageous in the case when a battery of a large
number of kinases needs to be screened.
4.1.2 Estimating pharmacological distances from environmental dis-
tances
To infer Dphar, it becomes necessary to identify the structural feature that governs drug
cross reactivity across paralog kinases. It is revealed in Chapter 3 that SAHBs constitute
such structural markers. Thus, we estimate Dphar from Denv obtained by comparing the
SAHB patterns of purported targets. The matrix Denv quantifies differences in the SAHB
patterns within the ATP pockets (i.e. the drug binding site) across all kinase pairs. Thus,
the environmental distance is based on structural alignment followed by comparison of
poorly conserved features. The determination of SAHBs is following the procedures in
Chapter 3.
In Section 3.2 we already showed the correlation between Dphar and Denv when the for-
mer is obtained from the T7-bacteriophage kinase display screening against a background
of 17 drugs(Fabian et al., 2005). For each kinase pair (i, j), we can then infer the pharmaco-
logical distance using the linearly fitted parameters. Figure 3.9 is plotted with normalized
pharmacological distances. For the purpose of inference, here we replot the correlation
with original pharmacological distances (Figure 4.3) and use the fitted parameters based
on such data:
Dphar(i, j) = 1985.5Denv(i, j)+7.0307 (4.1)
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Figure 4.3: Correlation between environmental and pharmacological distances. Each di-
amond represents a pair of kinases with horizontal coordinate being the environmental
distance and vertical coordinate being the pharmacological distance between them. Unlike
Figure 3.9, the environmental distances in this figure are not normalized. The straight line
indicates the linear fit by least-squares method: Dphar(i, j) = 1985.5Denv(i, j)+ 7.0307.
Note that the correlation is very tight (R2 ∼ 0.92).
In the process of inferring Dphar from Denv, some errors are introduced in the estimated
pharmacological distances. There are at least two possible sources of errors leading to
dispersion in the correlation:
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a) The background of drugs used to define the pharmacological distance is limited, with
uneven target coverage, and thus only approximately indicative of pharmacological
behavior.
b) The SAHBs are not the only selectivity determinant for nonpromiscuous drugs.
In regards to error source (a), we are limited in our analysis by the availability of drugs
chosen to define pharmacological profiles in high-throughput experiments (Fabian et al.,
2005). We may need to revise Dphar as new screening data becomes available. In regards
to (b), we can only claim that SAHBs are one determinant but not necessarily the only
factor governing ligand specificity (Chen et al., 2007). Even though these errors will be
inherited in the following steps, we made the method less sensitive to systematic errors
through adequate parameterization.
4.1.3 Expanding pharmacological information from limited affinity
profiles
We now show how to determine the affinity profiles of kinases from structure-based
estimations of pharmacological distances between kinase pairs. Just like vector coordinates
cannot be uniquely determined from vector distances, affinity profiles cannot be uniquely
determined solely from the pharmacological distances: additional constraints are required.
To solve the profile prediction problem, we cast it in terms of linear algebra, through a
(vector) ↔ (kinase profile) correspondence. The procedure boils down to determining
vector coordinates given distances between vectors. To guarantee the uniqueness of the
solution, a subset of vectors should be given in addition to vector distances. Thus, for given
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pharmacological distances between pairs of kinases, the number of independent degrees of
freedom of the solution vectors (kinase profiles) is n, which corresponds to the number of
inhibitors, i.e., the dimension of the affinity-profile space. Therefore, we need to know
at least n independent vectors to determine all affinity profiles. These conditions narrow
down solutions to two possibilities, due to symmetry. Reflection relative to the hyperplane
determined by the fixed n independent vectors produces two conjugate solutions to the
problem (see the example in Figure 4.4). Thus, to unambiguously determine the solution,
we need the coordinates of an additional vector. Accordingly, the minimal number of fixed
vectors should be n + 1. A constraint on these n + 1 vectors is that n of them should be
linearly independent, i.e., they should not be within one (n-1)-dimensional hyperplane.
To summarize, we may re-cast the profile prediction problem in linear-algebra terms
through the following correspondences:
Space dimension↔ Number of sampled inhibitors
Distance↔ Pharmacological distance
Vector↔ Affinity profile of kinase (against a background of inhibitors)
Vector xi ↔ Experimentally determined profile of the ith kinase in the subset
Vector y↔ Affinity profile of the test kinase
Thus, the in silico profiling problem may be cast as a linear-algebra problem as follows:
In an n-dimension space, we have n + 1 given vectors (the subset) with n of them being
linearly independent:
xi, i = 0,1,2, ...,n (4.2)
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Figure 4.4: A 3-dimensional example illustrating the neccessary conditions to uniquely
determine a system of points. (a) In 3-dimensional space, a group of points with all the
distances between them are given. If only the coordinates of three points (A, B and C)
are provided, then there are two possible cases satisfying the conditions, which are are
symmetric to each other with respect to the plane determined by the three given pionts,
A, B and C. (b) If the coordinates of one more point D that is not in the A-B-C plane are
provided, then the conditions are enough to unambiguously determine the solution.
Note that xi is the profile vector of kinase i against the n inhibitors. That is, xki equals to
the negative logarithm of the dissociation constant between kinase i and inhibitor k. For a
generic vector y ( affinity profile of a test kinase) that is not in the subset, we have estimated
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the distances di from y to all xi ’s:
di = |y−xi|, i = 0, ...,n (4.3)
Our purpose is to determine the coordinates of vector y based on the conditions given
above. Note that y is the profile vector of a kinase that is not in the subset to be screened
by experiment, i.e., y is one of the profile vectors to be determined in silico. We now show
that this can be achieved by linear algebra calculation.
Since n of the n + 1 vectors are linearly independent, we can assume without loss of
generality that x1, · · · ,xn are the independent vectors. We first define x′i = xi − x0, for
i = 1,2, · · · ,n. Note that all x′i are linearly independent. Similarly, we define y
′ = y−x0.
Note that now we only need to determine y′ to obtain y. We can determine the scalar
product of y′ with each x′i using the information on the vector distances and the well known
relation |y′− x′i|
2 = |y′|2 + |x′i|
2− 2y′ · x′i, in turn obtained from the definition of scalar
product:
αi = y
′ ·x′i
= (|y′|2+ |x′i|
2−|y′−x′i|
2)/2
= (|y′|2+ |x′i|
2d2i )/2
where the last expression indicates how αi can be evaluated from the estimated distances.
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We then have a system of n-variable linear equations by rewriting the relationships above
x′1 ·y
′ = α1
x′2 ·y
′ = α2
· · · · · ·
x′n ·y
′ = αn (4.4)
Thus the pharmacological problem of determining the profiles of test kinases boils
down to solving the system of linear equations (4.4), to obtain y′ and thereby y = y′+x0.
Note that each test-kinase profile y is represented as a row in the “predicted affinity
profiles” in the scheme shown in Figure 4.2.
This calculation can be repeated for each test kinase not included in the subset of exper-
imentally screened kinases. By calculating the “predicted affinity profiles” row-by-row, we
then extend the sub-profile to an entire affinity profile over all kinases for which structural
information is available (and hence pharmacological distances may be estimated).
4.1.4 Prediction of affinity profiles
In order to find the affinity profile of a new inhibitor, we first obtain its affinity sub-
profile against the kinases in the subset. We treat the inhibitor as one of the linear dimen-
sions of the pharmacological distance space. As shown above, we calculate the affinities of
all the inhibitors, including the new one, towards the kinases that are not within the subset.
In this way, the entire profile of the new inhibitor is obtained.
In an ideal case as a mathematical model, if the estimated Dphar were highly close
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to the real values, we could obtain the quantitatively exact profile (i.e., exact values of
Kd’s or ∆G’s). Unfortunately, the correlation of R2 ∼ 0.92 is still not tight enough for a
quantitative profile prediction. Alternatively, we predict the profile in a qualitative level,
i.e., “hit” or “no hit”. At this stage, we use thresholds of the ligand-target dissociation
constant (Kd,threshold) to determine whether an inhibitor hits a specific kinase or not. That
is, if for a kinase-inhibitor pair the predicted Kd is smaller than Kd,threshold , then we make
a qualitative predicttion that the inhibitor binds to the kinase, i.e., a “hit”. Three thresholds
were used in our predictions: Kd,threshold = 1µM,10µM,and100µM.
Repeating these steps on all test compounds, a large library profiling can be gener-
ated from a small-scale (i.e. sub-profile size) experiment. The process is schematically
represented in Figure 4.1 and Figure 4.2.
4.1.5 Finding the optimal basis set
The choice of kinases in the basis set (the subset) is crucial for the predictor’s perfor-
mance. First of all, a required condition for the subset is that the affinity vectors corre-
sponding to the kinases span all dimensions of the affinity space. Furthermore, some of the
kinases discriminate the inhibitory compounds less effectively than the others, i.e., com-
pounds’ affinities to them are more uniform than that to others. If such kinases are included
in the subset, the prediction would be more sensitive to errors in the estimated pharmaco-
logical distances. This would yield larger errors in the predicted affinity vectors. We then
designed a simple algorithm to examine and optimize a series of subset choices. First,
the predicted results are benchmarked against the experimental results (Fabian et al., 2005)
and the accuracies (percentages of the correct predictions) are calculated. We compared our
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predicted results on 17 inhibitors out of the 20 in the screening experiment(Fabian et al.,
2005) excluding three promiscuous inhibitors (Staurosporine, EKB-569 and SU11248),
against 119 kinases. For the 17×119 entries, we counted the number of entries correctly
predicted, in the “hit or no hit” level, and calculated the percentage of correct predictions.
Using this percentage as scoring function of the subset-choice, we performed optimiza-
tions for the basis set and found several sets with correct prediction percentages around
93%. Our algorithm to optimize the basis set is shown in the pseudo code below:
FOR each kinase in the basis set,
• replace this kinase with each kinase not in the set;
• predict the profile;
• benchmark the predictive results and calculate the accuracy;
• IF the current percentage is higher than the existing best one;
THEN use this kinase in the place of the original kinase in the set;
END LOOP
Note that this algorithm does not guarantee an optimal basis but only provide a nearly
optimal one. The real optimal basis set is extremely hard to find and may only improve the
accuracy of the prediction by one or two percentage points from the nearly optimal ones.
61
4.2 Validation of the Profiler
4.2.1 Experimental validation of affinity predictions
The affinity prediction is validated by benchmarking the result for all the nonpromis-
cuous inhibitory compounds in the phage-display kinase assay against the experimen-
tal data(Fabian et al., 2005). The compounds used in the benchmark are: SB202190,
SB203580, VX-745, BIRB-796, SP600125, Gleevec, Iressa, Tarceva, ZD-6474, CI-1033,
GW-2016, Vatalanib, MLN-518, LY-333531, BAY-43-9006, Roscovitine and Flavopiridol.
For randomly chosen kinase subsets prior to any optimization, mostly the accuracies of the
predictions are around 80∼ 90%. 1 For instance, consider the randomly chosen subset of
kinases:
AAK1, ABL1, CDK2, EGFR, ERBB2, FLT3, GAK, JNK1, KIT, LCK, p38-alpha,
PDGFRB, PHKG1, SLK, SRC, STK10, VEGFR2, YES.
Using this subset, the profiler predicts affinities for all 119 kinases independently as-
sayed (Fabian et al., 2005) with 252 false positives and false negatives out of 17× 119
predictions, for the affinity threshold 10µM. The corresponding accuracy is 88%. Notice
that the 17×119 predictions cover the sub-profiles for the subset and the accuracy is cal-
culated based on all 17×119 predictions. This does not weaken the validation since when
predicting for a kinase within the subset, the input distances are obtained independently,
i.e. estimated from environmental distances. In other words, the predictor does not dis-
criminate kinases within or outside of the subset. In a real work, it is useless to predict the
1Low accuracies (around 60%) are present but rare. These low accuracies arise from the choices of the
kinase subsets extremely vulnerable to the errors introduced in previous step. This is also why we need to
perform optimizations - to avoid such choices of subsets.
62
affinities of an inhibitor for kinases within the subset, but here we just include these results
for the sake of validation.
The next step is to optimize the subset of kinases to improve prediction accuracy. For
the purpose of validation, we perform the optimization with a “leave-one-out” algorithm.
That is, to predict the profile of one inhibitor, we apply the optimization algorithm dis-
cussed above to the other 16 inhibitors and thereby get an optimized subset of 17 (=16+1)
kinases. These 17 kinases plus one more randomly chosen kinase constitute the subset
used for the prediction of the inhibitor. In this way, the inhibitor profile to be predicted
is left out of the subset optimization process, and thus the optimized choice of the subset
is completely independent of the inhibitor left out, though it might not be the best choice
since one kinase in the subset is chosen randomly. It is possible that the randomly chosen
kinase plus the 17 optimized ones do not constitute a complete subset (dimension < 17),
rendering equation 4.4 not solvable. In this case, we simply replace the randomly chosen
kinase with another random one until the corresponding equation 4.4 becomes solvable.
As an example, the optimized subset used to predict the profile of SB202190 is as follows
(the first 16 kinases result from optimization while the last one is randomly chosen):
INSR, PTK6, CSNK1G1, TEK, Aurora2, EPHA3, PHKG2, BIKE, EPHB4, FYN,
TNIK, DAPK2, FGFR1, SLK, PRKAA1, ERBB2, YES, p38-beta.
We predict the complete affinity profiles of the 17 inhibitors one by one, using the
profiling information of the 17 inhibitors against the 18-kinase subset. Before predicting
for each inhibior, a subset optimization based on the other 16 inhibitors is carried out. That
means the subset used in the profile prediction for each one of the 17 inhibitors is not
necessarily the same in each case.
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The accuracy of our predictor, as revealed by Figure 4.5, is quantitatively summarized
in Table 4.1 . In accord with Figure 4.5 , we use three thresholds for kinase-inhibitor
hit/no-hit results: Kd,threshold = 1µM,10µM,and100µM. The accuracy of the predictions
are 91%, 93% and 93%, respectively. When usingKd,threshold = 1µM, the errors are mainly
due to false positives, while for Kd,threshold = 10µM and 100µM they arise mostly from
false negatives. Thus we can choose different Kd,threshold’s for different purposes. If we
are concerned with drug specificity and promiscuity in a clinical context, it is reasonable
to use Kd,threshold = 1µM since it imposes a more stringent criterion for affinity, suitable
for clinical purposes. If binding is the sole concern, a better choice would be Kd,threshold =
10µM or 100µM, since these filters entail higher sensitivity.
Table 4.1: Prediction accuracy with different filters for hit/no-hit
Kd,threshold 1µM 10µM 100µM
False positive† 116 9 36
False negative‡ 69 133 114
Accuracy 91% 93% 93%
† False positive refers to “no hit” predicted as “hit”. ‡ False negative refers to “hit” predicted as “no hit”.
The performance and confidence of our predictor are affected by two factors: error
sources and the predictor’s vulnerability to errors. The major error source in this algo-
rithm arises from the computational estimation of kinase pharmacological distances from
environmental distances, which is determined by the tightness of the correlation. Thus,
the predictor may perform not so well in the cases where the profile of the compound to
predict is not subject to the correlation. The reasons why the correlation is not perfect
and the factors affecting the correlation have already been discussed in Section 4.1.2 and
may include alternative structural features nonconserved across paralogs. Here we dis-
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Figure 4.5: Matrices of prediction performance, corresponding from left to right to affinity
thresholds Kd = 1µM, 10µM , and 100µM, respectively. The complete affinity profiles of
17 inhibitors independently screened(Fabian et al., 2005) were predicted one by one, using
the experimental profiling information on the 17 inhibitors against an 18-kinase subset
(different for each inhibitor). Green cells indicate correct predictions; blue, false negatives
(“hit” predicted as “no hit”); red, false positives (“no hit” predicted as “hit”). The accuracy
percentages shown in the three matrices are 91%, 93% and 93%. Detailed quantitative
summary of the accuracy is in Table 4.1.
cuss the practical aspect of the problem: for what kinds of compounds would the predictor
work successfully? The 17 compounds we adopted in our analysis represent various types
of compounds: SB202190, SB203580, and SP600125 are research compounds; MLN518
is in phase I; VX745, CI-1033, ZD6474, Roscovitine, and Flavopiridol are in phase II;
BIRB-796, GW-2016, Vatalanib, LY-333531, and BAY-43-9006 are in phase III; Gleevec,
Iressa, and Tarceva are approved drugs(Fabian et al., 2005). This diversity suggests that
the predictor would work well in a wide range of compounds. However, there are highly
promiscuous compounds, such as Staurosporine, whose profile cannot be fitted into the
structure-pharmacology correlation (Section 3.2) and hence our predictor would fail to
yield a reliable result.
Another important factor influencing predictor confidence is its robustness or vulner-
ability to errors introduced in the distance estimation. This is mainly determined by the
choice of kinases in the small-scale sample, the affinities for which constitute the sub-
profile. Some of the kinases differentiate the inhibitory compounds better than others, i.e.
compounds’ affinities for them are more rigorous. It is better to include such kinases in the
sub-profile, since such basis subsets are less sensitive to the errors in the estimated phar-
macological distances. This problem is handled by the optimization process, in which the
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subset of kinases that performs best within the training set is chosen (Section 4.1.5).
4.2.2 Validating the predicted affinity profile of a re-designed version
of imatinib
To further validate our predictor, we focus on a recently developed kinase inhibitor,
WBZ_4 (Figure 4.6), a redesigned version of the powerful anticancer drug imatinib (Gleevec)
with higher specificity than the parental compound(Fernández et al., 2007). The prototype
compound WBZ_4 does not belong to the drug background used in the high-throughput
screening previously adopted as benchmark for our method. The interest in this compound
arises because the WBZ_4 design was meant to enhance specificity beyond imatinib levels
guided precisely by the same structural markers, the SAHBs that we exploited to calculate
pharmacological distances and thus infer cross reactivities. Thus, we now validate our ap-
proach by predicting the affinity profile ofWBZ_4, and contrasting it with the experimental
profile obtained from Ambit’s phage-display screening assay reported in ref. of Fernández
et al. (2007).
The compound WBZ_4 was developed by redesigning imatinib for the purpose of in-
hibiting the C-Kit kinase, as imatinib does, while avoiding another primary imatinib target,
the Bcr-Abl kinase. The latter target has been directly implicated in imatinib’s cardiotox-
icity(Kerkela et al., 2006). In addition, WBZ_4 was designed to inhibite JNK1, a major
target to protect the cardiomyocytes from a mitochondrial collapse induced by Bcr-Abl
inhibition(Fernández et al., 2007; Kerkela et al., 2006).
The prototype has been experimentally profiled using the screening methodology based
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Figure 4.6: Prototype molecule WBZ_4 (N-{5-[4-(4-methyl piperazine methyl)-
benzoylamido]-2-methylphenyl}-4-[3-(4-methyl)-pyridyl]-2-pyrimidine amine). It is de-
veloped by adding a methyl group (indicated in red) to the imatinib molecule.
on bacteriophage kinase display(Fabian et al., 2005; Fernández et al., 2007). In the predic-
tion, the kinase subset has been optimized in consonance with the drug background of 17
nonpromiscuous compounds extracted from the Ambit’s screening (Section4.1.5). The ex-
perimental and the predicted results are contrasted in Figure 4.7. The experimental results
for the affinities of WBZ_4, reported in ref. Fernández et al. (2007), covered 107 of the
119 kinases reported in Fabian et al. (2005), excluding ACK1, Aurora2, Aurora3, NTRK1,
PRKAA1, PRKACA, STK10, STK18, STK3_m, STK38L, TEK, and ULK3_m. Due to
the emphasis in the pharmacological applications of the prototype compound and the clin-
ical significance of achieving nanomolar inhibition, the theoretical predictions were made
adopting a stringent threshold Kd,threshold = 100nM, that is, a hit was recorded as such only
if the predicted Kd < 100nM. Of the 107 predictions, there is no single false negative and
only 2 false positives: LCK and JNK2, as shown in Figure 4.7. This corresponds to an ac-
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Figure 4.7: Experimental and predicted re-
sults for the affinity profile of WBZ_4
against 107 kinases. The experimental
results for the affinities of WBZ_4, re-
ported in Fernández et al. (2007), covered
107 of the 119 kinases reported in Fabian
et al. (2005), excluding ACK1, Aurora2,
Aurora3, NTRK1, PRKAA1, PRKACA,
STK10, STK18, STK3_m, STK38L, TEK,
and ULK3_m. The subset adopted in
this prediction has been optimized in ad-
vance, within a training set excluding
WBZ_4. The optimized subset con-
tains: ABL1(E255K), CAMK1, EPHA8,
ERBB2, FLT3, FRK, GAK, INSR, JNK1,
KIT, MAP3K4, PDGFRB, PHKG1, PIM1,
PRKAA1, RPS6KA2, SLK, SRC. Due to the
emphasis in the pharmacological applications
of the prototype compound and the clinical
significance of achieving nanomolar inhibi-
tion, the theoretical predictions were made
adopting a stringent threshold Kd,threshold =
100nM, that is, a hit was recorded as such
only if Kd < 100nM. Of the 107 predictions,
there is no single false negative and only 2
false positives: LCK and JNK2. This corre-
sponds to an accuracy above 98%.
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curacy above 98%. Most importantly, our predictor correctly identified C-KIT and JNK1
as primary targets for WBZ_4 and correctly predicted the lack of pharmacological activity
against Bcr-Abl, a crucial premise in the planned imatinib redesign geared at curbing its
potential cardiotoxicity.
4.2.3 Comparative assessment of performance
One docking-based method was recently reported and claimed to be the best for com-
puting the affinities of inhibitors for homologous receptors (Rockey and Elcock, 2005).
The authors compared their predictions with the experimental results published by Fabian
et al. (2005). and found "a reasonable but not perfect correspondence" (Rockey and Elcock,
2005). Both this work and our profiler predicted the affinity profile of imatinib (Gleevec)
against extended lists of kinases, and thus the results can been compared. Benchmarked
by the experimental profiles(Fabian et al., 2005), the docking-based prediction contains
9 false negatives (CLK1, CLK4, EPHA8, GAK, JNK1, JNK2, JNK3, STK17A, STK18)
and 8 false positives (ACK1, BMX, CSK, FGR, HCK, LYN, RIPK2, YES) out of the 119
kinases2, while our profiler has only 2 false negatives (ABL1(T315I), STK18) and 1 false
positive (STK10) with the 10µM threshold (Figure 4.5).
Furthermore, the docking-based method is more demanding than our profiler in terms
of primary experimental data, since it requires the "high-resolution structure in complex
with at least one protein kinase target" for each inhibitor to make appropriate prediction
(Rockey and Elcock, 2005). The successful generation of such data is plagued with experi-
2The docking-based prediction calculated the affinities of Gleevec for 493 human protein kinases, which
are almost the whole human kinome. The 9 false negatives and 8 false positives are only the ones within the
119 kinases tested in the experiments of Fabian et al. (2005).
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mental uncertainty as crystallization remains a serendipitous craft rather than an automated
methodology. By contrast, our profiler requires the affinity sub-profile of the inhibitor
against ∼ 20 protein kinases, which can be routinely obtained through phage displayers of
kinase batteries or other screening methods.
4.3 Conclusion
In this chapter, we introduced a method to predict affinity profiles of inhibitor com-
pounds against entire batteries of human kinases based on a structural descriptor of the
targets. The method is rooted in a molecular marker governing drug specificity and promis-
cuity established in our previous work. A feature-similarity matrix constructed based on
the molecular marker is defined across kinase targets and used as an information propaga-
tor of a sub-profile where drugs are screened against a small group of kinases. The method
reported makes use of distance-geometry techniques, and boils down to determining vec-
tors (kinase profiles) from distances between vectors (feature-similarity distances regarded
as surrogates for pharmacological distances between kinases). To guarantee the uniqueness
of the solution, some vector coordinates need to be fixed and adopted as constraints. These
constraints represent the linear algebra counterpart of the sub-profile. Our in silico method
enables us to screen large libraries of compounds predicting their profile. To provide the
input data, only a limited experimental screening against reduced subset of kinases needs to
be performed in advance. Thus, our predictor becomes a valuable tool for lead discovery.
The linear-algebra operations subsumed in our predictor are based on the construction
of the informational propagator and hence do not entail any source of errors. The only
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systematic source of uncertainty arises from the estimation of pharmacological parameters
from structure-based attributes (environmental distances). Given the high accuracy (for
a qualitative prediction) of the pharmacological distance estimation, our profiling method
should be deemed highly reliable: the accuracy is up to 93% with an optimized choice of
kinase subset as starting point, as shown above.
Alternative in silico screening methods rooted in docking algorithms are unlikely to
match this level of accuracy, not only because of their inherent parametric uncertainty and
time expense, but also because kinase binding entails extensive induced fit of the loopy
regions within the ATP-pocket (Huse and Kuriyan, 2002). Even those docking algorithms
that incorporate induced fits into affinity calculations cannot handle the lengthy loopy re-
gions of kinases, which undergo extensive structural adaptation (Mizutani and Itai, 2004;
Mizutani et al., 2006). The induced fit problem as it stands today remains intractable from
first-principle aproaches. This is the main reason why we adopted an information-based
algorithm for our predictor.
Chapter 5
Redesigning kinase inhibitors to
enhance specificity
In this chapter we introduce a technique that turns promiscuous kinase inhibitors into
safer drugs. This technique adopted the structrual marker identified in Chapter 3 that is
governing the specificity in molecularly targeted drug therapy. This technique is developed
besides the recently burgeoning interest in multi-target drugs to treat complex diseases and
malignancies. Thus in this chapter we first briefly discuss the assessment of the therapeutic
value of promiscuity: Although drug efficacy might not correlate with specificity, it would
be risky to welcome promiscuous compounds without a rational strategy to control thera-
peutic impact. This is the motivation for us to survey approaches to control the therapeutic
impact of cross-reactive kinase inhibitors and advocate the application of the selectivity
filter by illustrating its cleaning efficacy.
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5.1 Assessment of the therapeutic value of promiscuity
Small-molecule inhibitors of protein function are the most common and efficient agents
for molecularly targeted therapy geared at treating human disease and malignancy (Dancey
and Sausville, 2003; Levitzki and Gazit, 1995; Tibes et al., 2005; Gibbs and Oliff, 1994;
Donato and Talpaz, 2000). The undesirable side effects arising from drug cross-reactivity
and from the diversity of roles of the target in different biological scenarios prompted
researchers to advocate for a “magic-bullet” paradigm (Roth et al., 2004), epitomized by
compounds with high binding specificity.
However, there is no obvious correlation between drug specificity and therapeutic in-
dex1(Roth et al., 2004; Frantz, 2005; Keith et al., 2005; Mencher and Wang, 2005; Mc-
Govern et al., 2003; Feng et al., 2005). This is especially true for kinase inhibitors since
kinases play different signal-transduction roles in different cellular contexts and a favor-
able inhibition in one scenario may prove fatal in another one (Force et al., 2007). For
instance, a specific inhibitor of the Abelson (Abl) kinase would be presumed to be most
efficacious in treating chronic myeloid leukemia (CML), since an aberrantly deregulated
Abl kinase is a recognized primary target for treating this malignancy (Donato and Talpaz,
2000). However, a systems biology assessment (Force et al., 2007) has recently revealed
that Abl inhibition is a culprit for cardiotoxicity. Abl inhibition initiates a signaling cascade
that promotes mitochondrial depolarization and hence a health-threatening ATP-depletion
in cardiomyocites. Thus, a more cross reactive drug, i. e., one that also inhibits another
kinase along the mitochondrial-depolarization pathway (hence blocking it) is expected to
1Lethal dose (LD50) over therapeutically effective dose (ED50)
74
have a higher therapeutic index in treating CML: Higher therapeutic doses may be tolerable
due to the removal of cardiotoxic side effects, as recently demonstrated (Fernández et al.,
2007; Demetri, 2007; Crunkhorn, 2008).
Furthermore, much effort is recently directed at reassessing the therapeutic value of
promiscuity. This paradigm shift is in part motivated by telling cases. For instance, the
schizophrenia drug Clozaril (clozapine) works because of its multi-target action, in spite
of unpleasant side effects (Roth et al., 2004). Other illustrations of the clinical relevance
of cross-reactive (“dirty”) drugs have arisen in anticancer therapy: multi-target kinase in-
hibitors such as Sutent (sunitinib) or Nexavar (sorafenib) have recently received FDA ap-
proval (Frantz, 2005; Force et al., 2007), albeit with important caveats2.
In general, the possibility of exploiting promiscuity is under scrutiny in novel ap-
proaches to treat complex disorders such as cancer, depression and cardiovascular disease
(Frantz, 2005). Modulating multiple targets simultaneously is often required to alter a clin-
ical phenotype, as biological redundancies and alternative pathways can often bypass the
inhibition of a single target or of multiple targets along a single pathway(Hopkins et al.,
2006). Thus, a “magic-shotgun” compound targeting multiple proteins may in some in-
stances possess a higher therapeutic index than a specific drug (Roth et al., 2004).
Another argument for promiscuity arises with the observation that dirty or cross-reactive
drugs may be more resilient against drug-resistant mutations (Hampton, 2004). Cross re-
activity arises because such drugs typically make ligand-target interactions with evolution-
arily conserved residues and with backbone groups, and weaker interactions with primary
mutated residues (Hampton, 2004; Hopkins et al., 2004). Obviously, targeting conserved
2see: http://www.fda.gov/cder/cancer/druglistframe.htm
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residues or unspecific parts of the chain (backbone) begets promiscuity.
The safety of dirty drugs, especially dirty kinase inhibitors, is often associated with the
possibility of assessing the full extent of their cross reactivity (Owens, 2006). In turn, this
assessment is facilitated by the advent of novel high-throughput screening assays such as:
a) the kinase assay using the T7-phage expression panels from Ambit Biosciences (Fabian
et al., 2005; Karaman et al., 2008); b) a thermal stability shift assay using a 60-Ser/Thr
kinase panel (Fedorov et al., 2007a); c) the BioPrint database by Cerep (Krejsa et al.,
2003); and d) the living-cell assays of pathway inhibition that assess the impact of the drug
on the protein-recruiting capability of the target (MacDonald et al., 2006).
In vitro assays of cross reactivity are of course affected by the complexities of tis-
sue distribution and, generally, by pharmacodynamic issues (Brunton et al., 2005). Yet,
the affinity of a drug for a target, being governed by thermodynamics of ligand binding,
represents a telling parameter independent of in vivo heterogeneities, except for allosteric
antagonism (Brunton et al., 2005). On the other hand, crowding, membrane adsorption
and other effects can modulate in vivo drug concentrations, increasing local levels in dif-
ferent spatial locations. Thus, certain cross-reactivities undetectable in vitro may surface in
an in vivo context, causing unexpected side effects (Brunton et al., 2005; Rishton, 2005).
Conversely, tissue and subcellular distribution may prevent a ligand from binding an in-
vitro-established target, introducing another caveat in the interpretation of high-throughput
screening results.
In spite of timely efforts to establish a paradigm shift, promiscuous drugs lacking con-
trolled specificity obviously carry the burden of life-threatening side effects to a larger
extent than their more specific counterparts. Even the most successful anticancer drug
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Gleevec (imatinib), with a moderately reduced gamut of primary targets (limited to 5 ki-
nases: Bcr-Abl, C-Kit, Lck, PDGFR, and CSF1R (Fabian et al., 2005; Karaman et al.,
2008)), has been recently shown to be potentially cardiotoxic (Force et al., 2007; Hamp-
ton, 2004), and labeled as such by the FDA3. Not surprisingly, the more promiscuous
anticancer kinase inhibitors sunitinib and sorafenib have been also found to be cardiotoxic,
even to a larger extent than imatinib (Force et al., 2007; Hampton, 2004). In Ambit screen-
ings (Fabian et al., 2005) sunitinib was shown to bind 79 kinases out of 119 assayed, while
sorafenib binds to 41.
If multiple roles of a targeted protein in different cellular contexts may be responsi-
ble for side effects (Force et al., 2007), it is only natural that promiscuous compounds
would introduce a more uncertain clinical outcome. Hence, it becomes forbiddingly risky
to welcome promiscuous compounds into the therapeutic arena without a rational strategy
to control their specificity and therapeutic index. This control, in turn, requires the iden-
tification of selectivity filters in target space, which should serve as guidance to rational
design (Fernández et al., 2007; Fedorov et al., 2007b; Bogoyevitch and Fairlie, 2007; Cre-
spo and Fernández, 2007). In Chapter 3 we identified Solvent-Accessible Hydrogen Bond
(dehydron) as one of such filters. Now in this chapter, we advocate for this type of control
of therapeutic impact to clean dirty drugs following an integral assessment of the diverse
functional roles of targeted proteins. By focusing on kinase targets, we justify this posi-
tion, offers an avenue to clean dirty kinase inhibitors and demonstrates the feasibility of
the proposed approach by reviewing a proof of principle.
3see: http://www.fda.gov/medwatch/safety/2006/Gleevec_DHCP_10-19-2006.htm.
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5.2 Cleaning cross-reactive drugs by exploiting selectivity
filters
Most protein drug targets have paralogs, that is, proteins that share a common ancestor
with the target and have diverged away from it after speciation (Chen et al., 2007). Thus, ki-
nases, the widespread cancer targets, belong to common-ancestry groups (families) which
typically share the same fold and basic structural features. This structural conservation of-
ten results in unexpected cross reactivities that may lead to undesired side effects (Fabian
et al., 2005; Karaman et al., 2008; Griffin, 2005).
In principle, much of the cross reactivity may be removed by drug redesign guided by
the identification of structural features that promote promiscuity and nonconserved features
that enable paralog discrimination. This approach has been attempted with promising re-
sults (Fernández et al., 2007; Demetri, 2007; Crunkhorn, 2008), and supports our proposal
for “cleaning” kinase inhibitors.
There have been a number of paralog-discriminating nonconserved features that may
be exploited as selectivity filters, that is, as targetable differences (Fedorov et al., 2007b;
Bogoyevitch and Fairlie, 2007). One approach uses high-resolution crystal structures of
kinases in complex with non-ATP ligands to identify unique structural motifs in the pur-
ported targets. For example, a unique helical insert has been found in the activation loop
of the NEK2 and MPSK1 kinases following the conserved DFG catalytic triad (Fedorov
et al., 2007b).
Specific inhibitors that target inactive kinase conformations have also been developed
targeting the “DFG out” conformation (Liu and Gray, 2006). In this unique conformation,
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the position of the phenylalanine (F) residue, located at the start of the activation loop, is
flipped with respect to the active conformation, so that it points inwards within the ATP
pocket. This mode of association is illustrated by the binding of imatinib to the inactive
Abl kinase (Noble et al., 2004). In addition to the DFG-out motif, nonconserved struc-
tural features within the inactive ensemble should perhaps be exploited to achieve paralog
specificity. The inactive conformations of kinases make them more discernible, while the
active conformation reveals fewer discriminatory features since it is constrained to be cat-
alytically functional and hence more conserved. While targeting the inactive conformation
may be a logical choice, there are also advantages in targeting the active conformation.
The latter requires structure conservation for functional purposes, and hence it is less tol-
erant to drug-resistant mutations (Noble et al., 2004). The substrate-discriminatory amino
acid variations that tell kinases apart are mostly located in loopy regions framing the ATP-
pocket, rather than in the pocket itself, making them less accessible targets (Crespo and
Fernández, 2007; Noble et al., 2004).
In this regard, another way of approaching the specificity problem is the design of
allosteric kinase inhibitors (Bogoyevitch and Fairlie, 2007). These ligands are typically
more specific than ATP-competitive inhibitors, since they bind to residues outside the ATP-
pocket, which are typically less conserved (Bogoyevitch and Fairlie, 2007).
In this chapter, we present a strategy adopting the molecular basis for specificity in-
troduced in Chapter 3, Solvent-Accessible Hydrogen Bond (dehydron). The distribution
of dehydrons in the structure may be turned into an operational selectivity filter for two
reasons:
• Dehydrons may be targeted by drugs that further wrap them by binding to the protein
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(c.f. Section 2.2.2).
• Dehydrons are not conserved across paralogs (c.f. Section 3.2).
To assess conservation, we align the paralog structures and examine the microenviron-
ments of the aligned hydrogen bonds. Typically, while the bonds are conserved across
paralogs, their packing is not, and hence there are differences in the dehydron distribu-
tion (Chen et al., 2007; Fernández and Scheraga, 2003). The structure conservation across
proteins within kinase families enables the alignment (Chen et al., 2007).
Therefore, the differences in dehydron distribution on the protein surfaces constitute
promising selectivity filters to clean dirty inhibitors through redesign. Thus, their stickiness
arises since the association of a suitable “wrapping” ligand to the target protein containing
the dehydron entails further removal of water surrounding the latter (Chen et al., 2007).
5.3 A first validation of the approach
While various selectivity filters have been identified for the druggable kinome (Fedorov
et al., 2007b; Bogoyevitch and Fairlie, 2007), only the nonconserved wrapping patterns
were adopted to re-design drugs in order to re-focus their impact on clinical targets (Cre-
spo and Fernández, 2007). For example, imatinib has been re-designed to curb its potential
cardiotoxicity (Force et al., 2007; Kerkela et al., 2006) by introducing a wrapping modifi-
cation that removes its inhibitory impact on one of its primary targets, the Bcr-Abl kinase
(Fernández et al., 2007; Demetri, 2007; Crunkhorn, 2008). The inhibition of this kinase in
cardiomyocites has been shown to be causative of imatinib’s cardiotoxicity (Kerkela et al.,
2006). On the other hand, imatinib is known to be particularly effective in treating chronic
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myeloid leukemia (CML) precisely through its inhibitory impact on the Bcr-Abl kinase, a
constitutively active aberrant chimera (Schindler et al., 2000; Gambacorti-Passerini et al.,
1997). Furthermore, imatinib has additional primary targets (C-Kit, Lck, PDGFR, and
CSF1R (Fabian et al., 2005; Karaman et al., 2008)), with at least one, C-Kit, of proven clin-
ical relevance (Demetri, 2007). This information inspired imatinib redesign with one goal:
avoiding the Bcr-Abl kinase while retaining activity towards C-Kit, the primary target to
treat GIST (gastrointestinal stromal tumors) (Demetri, 2007). The structural alignment of
Abl (PDB.1FPU) and C-Kit (PDB.1T46) complexed with imatinib reveals a nonconserved
dehydron C673-G676 in C-Kit which aligns with a well-wrapped M318-G321 hydrogen
bond in Abl (Fernández et al., 2007) (Figure 5.1). This difference in wrapping at the cat-
alytic loop prompted the development of a methylated variant of imatinib that hampers
Abl inhibition while re-focusing the impact on c-Kit. The molecular basis for target dis-
crimination was established in vitro and through in vivo assays for antitumor activity. The
therapeutic impact of the modified compound was confirmed in novel GIST animal mod-
els, also corroborating a significant reduction in cardiotoxicity (Fernández et al., 2007;
Demetri, 2007; Crunkhorn, 2008).
This proof of principle reveals that dehydrons are indeed targetable features and hence
opens up the possibility of exploiting differences in dehydron patterns to guide the cleaning
of promiscuous inhibitors through molecular redesign.
We thus suggest a general strategy to clean dirty inhibitors by introducing “wrapping”
chemical modifications that preserve the drug chemotype (Hopkins et al., 2006) while tar-
geting unique dehydrons. The proof of principle here described serves as a first validation
for this approach.
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Figure 5.1: Aligned backbones (ribbon representation) of Bcr-Abl (PDB.1FPU, red) and C-
Kit (PDB.1T46, blue) kinases in their respective structurally adapted imatinib complexes.
The nonconserved dehydron C673-G676 (green) in C-Kit aligns with the well wrapped
M318-G321 hydrogen bond (gray) in Abl, and has been targeted by a methylation “wrap-
ping” modification of imatinib (yellow highlight) to achieve specificity.
5.4 A workable approach
Most kinase inhibitors are in principle susceptible of being turned into selective wrap-
pers of packing defects through minor chemical modification and without altering their
chemotype. Thus, clinically relevant compounds with considerable cross reactivities such
as sunitinib (55% hits over number of proteins screened (Karaman et al., 2008)), dasatinib
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(30%), EKB-569 (20%), sorafenib (20%) or erlotinib (15%) may be redesigned into drugs
with enhanced specificity using the wrapping design concept. As an illustration, let us
focus on cleaning EKB-569.
Figure 5.2: Kinase inhibitor EKB-569 (Wyeth-Ayerst, (Torrance et al., 2000)), a major
inhibitor of the epidermal growth factor receptor (EGFR) kinase
The irreversible kinase inhibitor EKB-569 (Wyeth-Ayerst, (Torrance et al., 2000)) was
launched as a major inhibitor of the epidermal growth factor receptor (EGFR) kinase
(IC50=38.5nM). Thus, its therapeutic interest to treat non-small cell lung cancer (NSCLC),
colorectal neoplasia and other EGFR-dependent solid tumors became apparent4. Phase I
and II trials for such therapeutic applications are currently closed (Torrance et al., 2000;
Erlichman et al., 2006). Recent high-throughput screening using a battery of 119 T7-phage
expressed kinases (Fabian et al., 2005) revealed 25 sub-micromolar targets for EKB-569,
making it a promiscuous drug with likely side effects. Other compounds such as Iressa
(gefitinib) and Tarceva (erlotinib) share the same “4-anilinoquinoline” chemotype (Wiss-
4see: http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=4056579
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ner et al., 2003), yet they are more specific EGFR inhibitors (Fabian et al., 2005). The
latter two gained FDA approval as anti-NSCLC agents5.
Here we applied to EKB-569 the general strategy as follows.
1. Identify and verify the “dirty part”, i.e., the source for the promiscuity.
2. Clean up the “dirty part” by removing the structure features in the compound that
cause promiscuity.
3. Search for a targetable feature (dehydron in this work) in the intended target kinase
that is not conserved across the kinase paralogs.
4. Further modify the compound by introducing “wrapping” group that preserves the
drug chemotype while targets the unique dehydron chosen in the previous step.
In the following sections, we will explicitly explain the cleaning procedure step by step.
5.4.1 Identification of promiscuity source
The EKB-569 promiscuity can be traced to its intermolecular interactions with highly
conserved residues within the EGFR kinase family. As shown in Figure 5.3, the terminal
acryl group in the ligand plays the role of electrophile in the irreversible Michael-adduct
reaction with the nucleophile-conserved residues Cys/Ser in the EGFR-paralog kinases.
The water-solublizing terminal N-dimethyl group of EKB-569 may also accelerate such
addition, serving as an intramolecular base catalyst for Michael reaction with the Cys or
5see: http://www.fda.gov/cder/cancer/druglistframe.htm
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Ser residues, due to the spatial proximity(Wissner et al., 2003). Another source of EKB-
569 promiscuity is the intermolecular electrostatic interaction between its cyanide group
and the gatekeeper residue (Thr or Met), typically conserved within the family (Figure 5.3).
Figure 5.3: Structural alignment of EGFR kinase (blue ribbon representation, atoms in
licorice) and the paralog TNK2 kinase (red ribbon representation, atoms in balls and
sticks), complexed with EKB-569 (licorice). Atoms are depicted following standard color
convention (chlorine in green, fluorine in light green). One source of EKB-569 promiscu-
ity is the terminal acryl group (magenta), the electrophile group involved in the Michael
reaction with the nucleophile-conserved residues Cys/Ser in EGFR and its paralog kinases.
The other source of drug promiscuity is the intermolecular electrostatic interaction between
its cyanide group and the conserved gatekeeper residue (Thr/Met) in the target protein. The
wrapping pattern of EGFR includes the poorly conserved Asp831-Gly833 dehydron that
may be targeted to achieve selectivity. TNK2 contains the same two promiscuity-fostering
features, while lacking the dehydron at the locus where EGFR contains the specificity-
promoting feature. Thus, targeting the latter will ensure a discriminatory binding of EGFR
without hitting TNK2, as experimentally corroborated.
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5.4.2 Statistical verification of promiscuity source
To validate these observations, we assessed the correlation between the affinities of
EKB-569 for the 48 paralogs of EGFR reported in PDB and the extent of residue conserva-
tion at the Michael reaction site and at the gatekeeper position. To do so, we aligned each
paralog structure with the EGFR structure and examined residues that align with Cys773
(Michael reactant) and Thr766 (gatekeeper). The aligning residues are listed in Table 5.1.
Then we built a logistic regression model (Agresti, 1996) to assess the correlation between
the affinities of EKB-569 for the EGFR paralogs and the extent of residue conservation at
the two key sites.The logistic regression model is built as follows.
Explanatory Variables: There are two explanatory variables: the types of residues align-
ing with Cys773 (Michael reactant) and Thr766 (gatekeeper), respectively. Since the
Michael reaction can take place only if the residue aligning with Cys773 is a Michael
reactant, i.e., Cys or Ser, we let the first explanatory variable, X1, to be 1 if the residue
is Cys or Ser, otherwise to be 0. Similarly, we let the second explanatory variable
X2 = 1 if the residue aligning with Thr766 is Thr or Met (possible intermolecular
electrostatic interaction with the cyanide group), and X2 = 0 otherwise.
Responding Variables: Naturally, the responding variable should indicate the affinity of
EKB-569 towards the 48 EGFR-paralogs. Here the responding variable Y represents
the affinity in a “hit/no-hit” level: Y = 1 if the dissociation constant (Kd) is smaller
than 3µM according to Fabian et al. (2005), and Y = 0 otherwise.
Null Hypothesis: The null hypothesis of the model is that there is NO statistically signifi-
cant correlation between the responding variable and the explanatory variables. This
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Table 5.1: Data for the logistic regression model
Kinase PDB Michael Gatekeeper X1 X2 Y
reaction site¶ position§
ABL1 1IEP ASN THR 0 1 1
AURKA 1MUO THR LEU 0 0 0
BTK 1K2P CYS THR 1 1 1
CAMK1G 2JAM GLU MET 0 1 0
CDK2 1AQ1 ASP PHE 0 0 0
CDK5 1UNG ASP PHE 0 0 0
CLK1 1Z57 SER PHE 1 0 1
CLK3 2EU9 ASN PHE 0 0 1
CSNK1G2 2C47 SER LEU 1 0 0
DAPK2 1ZWS GLU LEU 0 0 0
DAPK3 2J90 GLU LEU 0 0 0
EGFR 1M17 CYS THR 1 1 1
EPHA2 1MQB ALA THR 0 1 0
ERBB2 1OVC CYS THR 1 1 1
FGFR1 1AGW ASN VAL 0 0 0
FGFR2 1GJO ASN VAL 0 0 0
FLT3 1RJB ASP PHE 0 0 0
FYN 2DQ7 SER THR 1 1 1
HCK 1AD5 SER THR 1 1 1
INSR 1GAG ASP MET 0 1 0
JAK2 2B7A SER MET 1 1 1
JNK1 2NO3 ASN MET 0 1 0
JNK3 1PMN ASN MET 0 1 0
KIT 1T45 ASP THR 0 1 0
LCK 2OF2 SER THR 1 1 1
MAP3K5 2CLQ SER MET 1 1 0
MKNK2 2AC3 SER PHE 1 0 0
NEK2 2JAV ASP MET 0 1 1
P38-α 1A9U ASP THR 0 1 0
P38-γ 1CM8 ASP MET 0 1 0
PAK1 1YHV SER MET 1 1 1
PAK4 2CDZ ALA MET 0 1 0
PAK6 2C30 ALA MET 0 1 0
PAK7/PAK5 2F57 ALA MET 0 1 0
PDGFRb 1LWT ASP THR 0 1
PIM1 1XQZ ASP LEU 0 0 0
PIM2 2IWI ASP LEU 0 0 0
PKAC-α 2GU8 GLU MET 0 1
PTK2 2ETM GLU MET 0 1 0
RPS6KA5 1VZO GLU LEU 0 0 0
SLK 2J51 ALA ILE 0 0 1
SRC 2SRC SER THR 1 1 1
STK10 2J7T ALA ILE 0 0 1
STK16 2BUJ THR LEU 0 0 0
SYK 1XBC PRO MET 0 1 1
TIE2(TEK) 1FVR ASN ILE 0 0 1
TNK2(ACK) 1U46 SER THR 1 1 1
VEGFR2 2P2H ASN VAL 0 0 0
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hypothesis will be checked by the p-value of the model.
The date for the logistic regression model is listed in Table 5.1.
We fit the model with the data in Table5.1 using a web-based logistic regression model
fitting tool 6 and revealed that the EKB-569 affinity is indeed dictated by these two sources
of promiscuity: p-value=0.0015 indicates that we can reject the null hypothesis at a confi-
dence level as high as 99.75%. The goodness of the fitting result is listed in Table 5.2. Thus,
the hypothesis that the terminal acryl group and the cyanide group in EKB-569 (Figure 5.3)
are indeed the “dirty” moieties responsible for promiscuity is statistically confirmed.
Table 5.2: Goodness of the Logistic Regression Model Fitting
Chi Square degree of freedom p-value
13.0285 2 0.0015
5.4.3 Clean-up of promiscuity source
Having identified the sources of promiscuity, we proceeded to clean EKB-569 by in-
troducing the following chemical modifications (Figure 5.4):
a) Replace the double bond (the Michael acceptor) in the acryl group with a single bond.
b) Replace the cyanide group with a methyl.
Since one hydrophilic group (the cyanide) is replaced by a hydrophobic group (the
methyl) in step (b), it may decrease the solubility of the compound. To compensate against
the insolubility due to the hydrophobic effect of the methyl group, we make an additional
revision to the molecular structure:
6http://statpages.org/logistic.html
88
c) Shorten the hydrophobic tail at the No.7 position of the nitroquinoline such that the tail
in the new compound is only a methoxy.
After the clean-up step, the compound structure is as follows:
Figure 5.4: EKB-569 with its promiscuity sources removed (the replacing parts are colored
in blue)
5.4.4 Choosing unique dehydron and introducing “wrapping” modi-
fication
After removing the sources of promiscuity, we then seek wrapping-based targetable
feature in the original target of EKB-569, EGFR kinase. With the targetable feature identi-
fied, the next step is to introduce a wrapping modification in the drug to target the intended
feature. When EGFR is crystallized in the induced-fit conformation generated by an in-
hibitor (erlotinib) that shares EKB-569’s 4-anilinoquinoline chemotype (PDB.1M17), we
now find only four accessible dehydrons within the binding pocket (see Figure 5.5):
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Figure 5.5: Accessible dehydrons within the binding pocket of EGFR (1M17.pdb). Only
the backbone is illustrated (in gray) for clarity. Dehydrons are indicated by green virtual
bond connecting the α-carbons. There are other dehydrons present in the EGFR kinase,
but only those accessible ones within the binding pocket are labeled.
Asp831-Gly833, Gly697-Phe699, Gly697-Gly700, Gly772-Val821.
By examining the conservation of these four dehydrons across the 48 EGFR-paralogs,
we found the least conserved is dehydron Asp831-Gly833. Only 11 paralogs retain this
dehydron:
AURKA, CLK3, EGFR, ERBB2, FYN, LCK, PAK6, PAK7/PAK5, PIM2, SLK, STK10.
Figure 5.3 shows an example kinase TNK2, which does not retain the dehydron. Based
on the dehydron-conservation analysis, we choose this dehydron as the nonconserved se-
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lectivity feature to be targeted. To do so, we appended a methyl group at position 3 of the
terminal benzene ring that acts as a wrapper or protector of such feature (Figure 5.6 and
5.7).
Figure 5.6: Structural features promoting selectivity in EGFR kinase guiding EKB-569
cleaning redesign. EGFR kinase structure (same representation as above) complexed with
the prototype EKB-569 re-designed inhibitor (licorice representation). To remove EKB-
569 promiscuity, the acrylic double bond (Michael electrophile) is replaced by a single
bond and the gatekeeper-interacting cyanide is replaced by a methyl. To selectively target
EGFR, a methyl group is added to the terminal benzene ring as a wrapper of the barely
conserved Asp831-Gly833 dehydron.
5.4.5 Synthesis of the redesigned EKB-569
This re-designed EKB-569 molecule was synthesized in Eli Lilly and Company fol-
lowing a pathway that recapitulates the EKB-569 synthesis (Wissner et al., 2003). The
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Figure 5.7: EKB-569 with its promiscuity sources removed (the replacing parts are colored
in blue) and a methyl group (in red) added as a wrapper of the dehydron Asp831-Gly833
(see Figure 5.6) in EGFR.
synthesis is schemed in Figure 5.8 and the details is as follows.
7-methoxy-4-hydroxy-6-nitroquinoline-3-methyl (IV)
A mixture 54.4 g (0.324 mol) of I and 72.1 g (0.456 mol) of II in 210 mL of toluene
was refluxed for about 16 hs. The reaction was cooled in an ice bath, and the product
was filtered. This was washed with three portions of ether and then dried to give 85.4 g
of intermediate compound III (94.1%) as a mixture of cis/trans isomers which could be
recrystallized, in 80% yield, from 2-methoxyethanol. A portion of this compound (34.4 g,
0.123 mol) was added as a solid to 2.5 L of refluxing (256 ◦C) dowtherm under N2 in a 5 L
three-necked flask equipped with a mechanical stirrer and a thermometer under nitrogen.
The reaction mixture was stirred vigorously at this temperature for 1.25 hs and then cooled
to room temperature. The thick reaction mixture was diluted with 2 L of ether, filtered, and
washed with ether to yield 21.5 g (74.7% from III) of IV.
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Figure 5.8: Synthetic pathway of the redesigned EKB-569 inhibitor.
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7-methoxy-4-chloro-6-nitroquinoline-3-methyl (V)
18 g (77 mmol) of IV was refluxed with 120 mL of POCl3 under N2 for 2.5 hs in a 1 L
round-bottomed flask. TLC (EtOAc: hexane, 1:1) showed no starting material remaining.
The excess POCl3 was removed by rotary evaporation. The flask containing the solid
residue was cooled in an ice bath, and 600 mL of CH2Cl2 was added to dissolve the residue.
The resulting cold solution was added into a vigorously stirred solution of 250 mL ice-cold
saturated K2CO3 and stirred for 30 min. The organic layer was separated, washed, dried
(MgSO4), and evaporated to give 17.3 g (88.8%) of V.
4-(3-methyl-4-fluoro-5-chlorophenylamino)-7-methoxy-6-nitroquinoline-3-methyl (VII)
A solution of 24.4 g (96.5 mmol) of V and 15.2 g (96.5 mmol) of VI in 900 mL of 2-
propanol was refluxed under N2 for 3.5 hs. TLC (EtOAc: hexane, 1:1) showed no starting
material remaining. After standing at room-temperature overnight, the solid was collected
by filtration and washed with 2-propanol and ether to give 37.2 g (93.8%) of VII as HCl
salt.
4-(3-methyl-4-fluoro-5-chlorophenylamino)-7-methoxy-6-aminoquinoline-3-methyl (VIII)
The hydrochloride VII (34.2 g, 91.2 mmol) was mixed with 35.7 g (638 mmol) of iron pow-
der. A solution of 43.9 g (820 mmol) of NH4Cl in 280 mL of water was added followed
by 985 mL of CH3OH. The mixture was refluxed with mechanical stirring under N2 for 4
hs at which time TLC indicated complete reduction. The reaction mixture was filtered hot,
and solids were washed with 500 mL of boiling CH3OH. After the combined filtrate was
evaporated, the residue was partitioned between 1.5 L of warm ethyl acetate and 700 mL of
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saturated sodium bicarbonate solution. The organic layer was dried over MgSO4, treated
with activated charcoal, filtered, and evaporated to give a residue which was recrystallized
from CHCl3-hexanes giving 28.6 g (90.9%) of VIII.
4-dimethylamino-butanoic-acid-[4-(5-chloro-4-fluoro-3-methylphenylamino)-3-methyl-
7-methoxy-quinoline-6-yl]-amide (X)
A solution of 18.9 g (54.9 mmol) of VIII and 11.5 mL (65.9 mmol) of N,N-diisopropyl
ethylamine in 366 mL of anhydrous THF was stirred under N2 in an ice bath as a solution
of 12.1 g (79.6 mmol) of the acid chloride (IX) in 183 mL of THF was added over 15
min. The reaction vessel was sealed and stored in the freezer overnight. The solution was
evaporated, and the residue was partitioned between saturated NaHCO3 and EtOAc. The
organic layer was separated, washed, dried (MgSO4), and passed through a thin layer of
silica gel. The obtained solid was refluxed with 400 mL of CH3OH for 0.5 h. After being
cooled to room temperature, the solid was collected and washed with CH3OH followed by
hexane to give 21.1 g (77.8%) of X as HCl salt: Melting point 197-200; MS (ES+) m/z
459; 1H-NMR (DMSO-d6) δ : 9.73 (bs, 1H), 9.61 (s, 1H), 9.00 (s, 1H), 8.54 (s, 1H), 7.41
(m, 3H), 7.24 (m, 1H), 6.83 (dt, J = 5.6, J = 15.4 Hz, 1H), 4.35 (s, 3H), 3.07 (d, J = 5.1 Hz,
2H), 1.41 (s, 3H), 1.31 (s, 3H); Anal. (C24H28N4O2ClF HCl) C, H, N.
5.4.6 Prediction of the redesigned EKB-569’s profile
Based on the selectivity filter provided by the wrapping patterns, we predict the affinity
profile of our prototype. The prediction is based on the conservation of the EGFR dehy-
dron Asp831-Gly833 wrapped by the prototype (but not by EKB-569) and the existence
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of steric hindrances with nonpolar groups in the catalytic loop of the target structures. We
predicted as “hits” only those targets with a conserved dehydron in such position and no
steric hindrance. Of the 13 kinases retaining the dehydron, only 7 hits are predicted:
CLK3, EGFR, ERBB2, FYN, LCK, SLK, STK10.
The other six all have steric hindrance with the compound. In fact, these three kinases
do not bind with the original EKB-569 either (Fabian et al., 2005). In the cases where
the residues aligning with EGFR’s Asp831-Gly833 are not engaged in a dehydron or a
well-wrapped hydrogen bond, we examined whether such dehydron can be induced upon
ligand binding with minimal structural adaptation. This happens only if two residues are
not forming a dehydron or a hydrogen bond in the pdb file but would form a dehydron
(not a well-wrapped hydrogen bond) when the loop makes small changes which change
the distance between or the relative orientation of the two residues. We found that only in
BTK, PTK2 and SYK kinases this dehydron can be induced upon drug binding with no
steric hindrance with the catalytic loop, so they represent other “possible” hits. Thus, we
predicted 7 “hits” and 3 “possible hits”. The details of the prediction is listed in Table 5.3
5.4.7 Experimentally screening the redesigned EKB-569’s profile
To validate our strategy, a comparative high-throughput screening was conducted at
10µM EKB-569 and prototype over a battery of 228 human kinases displayed in a T7-
bacteriophage-expressing library (Ambit Bioscience, San Diego, CA). Figure 5.9 shows
the complete experimental screening result.
The experimentally obtained affinity profile for the prototype agrees almost perfectly
with our predicted profile (see the last two columns of Table 5.3): There is only one false
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Table 5.3: Prediction and Experimental Validation
Wrapping Steric Predicted Experimental Match
Kinase PDB classification hindrance affinity affinity prediction-experiment
ABL1 2GQG - NO HIT NO HIT YES
AURKA 1MQ4 Dehydron YES NO HIT NO HIT YES
BTK 1K2P Possibly induced NO Possible HIT HIT YES
CAMK1G 2JAM - NO HIT NO HIT YES
CDK2 1AQ1 - NO HIT NO HIT YES
CDK5 1UNG - NO HIT NO HIT YES
CLK1 1Z57 - NO HIT NO HIT YES
CLK3 2EU9 Dehydron NO HIT HIT YES
CNSK1G2 2C47 - NO HIT NO HIT YES
DAPK2 2A2A - NO HIT NO HIT YES
DAPK3 2J90 - NO HIT NO HIT YES
EGFR 1M17 Dehydron NO HIT HIT YES
EPHA2 1MQB - NO HIT NO HIT YES
ERBB2 1OVC Dehydron NO HIT HIT YES
FGFR1 1AGW - NO HIT NO HIT YES
FGFR2 1GJO - NO HIT NO HIT YES
FLT3 1RJB Possibly induced YES NO HIT NO HIT YES
FYN 2DQ7 Dehydron NO HIT NO HIT NO
HCK 1QCF - NO HIT NO HIT YES
INSR 1GAG - NO HIT NO HIT YES
JAK2 2B7A - NO HIT NO HIT YES
JNK1 1UKH - NO HIT NO HIT YES
JNK3 1PMN - NO HIT NO HIT YES
KIT 1PKG - NO HIT NO HIT YES
LCK 1QPC Dehydron NO HIT HIT YES
MAP3K5 2CLQ - NO HIT NO HIT YES
MKNK2 2AC3 - NO HIT NO HIT YES
NEK2 2JAV - NO HIT NO HIT YES
P38-α 1DI9 - NO HIT NO HIT YES
P38-γ 1CM8 - NO HIT NO HIT YES
PAK1 1YHV - NO HIT NO HIT YES
PAK4 2CDZ - NO HIT NO HIT YES
PAK6 2C30 Dehydron YES NO HIT NO HIT YES
PAK7/PAK5 2F57 Dehydron YES NO HIT NO HIT YES
PDGFRB 1LWP - NO HIT NO HIT YES
PIM1 1YXT - NO HIT NO HIT YES
PIM2 2IWI Dehydron YES NO HIT NO HIT YES
PKAC-α 2GU8 - NO HIT NO HIT YES
PTK2 2ETM Possibly induced NO Possible HIT HIT YES
RPS6KA5 1VZO - NO HIT NO HIT YES
SLK 2J51 Dehydron NO HIT HIT YES
SRC 2SRC - NO HIT NO HIT YES
STK10 2J7T Dehydron NO HIT HIT YES
STK16 2BUJ Possibly induced YES NO HIT Not screened
SYK 1XBB Possibly induced NO Possible HIT NO HIT NO
TIE2 1FVR - NO HIT NO HIT YES
TNK2 1U46 - NO HIT NO HIT YES
VEGFR2 2P2H - NO HIT NO HIT YES
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positive (FYN), and one semi-false negative: SYK, which is predicted as “possible hit” but
not bound by the redesigned EKB-569.
The confirmation of the predictions by the experiments suggests that we have not only
successfully cleaned the dirty inhibitor EKB-569, but also controlled the therapeutic impact
in a predictable manner.
Summary of this section: We successfully cleaned the dirty inhibitor EKB-569 us-
ing an approach based on a selectivity filter. This was accomplished by first removing the
chemical features that promote promiscuity. Subsequently, we introduced a wrapping mod-
ification to target a non-conserved dehydron in the intended target and made the prototype
more selective than the parental compound.
5.5 Conclusion
As we have argued, therapeutic efficacy may not correlate with drug specificity, as
revealed in treatments of complex disorders and malignancies (Roth et al., 2004; Frantz,
2005; Keith et al., 2005; Mencher and Wang, 2005; McGovern et al., 2003; Feng et al.,
2005; Hopkins et al., 2006). This has motivated a reassessment of the therapeutic value
of promiscuity and may well trigger a paradigm shift, from “magic bullets” to multi-target
therapies (Frantz, 2005; Hopkins et al., 2006). These conceptual leaps are supported by the
advent of novel high-throughput screening technologies enabling an assessment of cross
reactivities (Fabian et al., 2005; Karaman et al., 2008; Fedorov et al., 2007a; Krejsa et al.,
2003), of the breadth of therapeutic impact and hidden phenotypes (MacDonald et al.,
2006), and of likely side effects (Force et al., 2007; Kerkela et al., 2006).
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However, knowing the realm of activity of these “magic shotguns” (Roth et al., 2004)
is insufficient to warrant broad therapeutic application. The uncertainties they introduce
in treatment outcome are likely broader than the more limited side effects associated with
more specific drugs (Force et al., 2007; Kerkela et al., 2006). Not surprisingly, the phar-
maceutical industry still holds a parochial approach in the face of such safety uncertainties
(Frantz, 2005; Hopkins et al., 2006).
At this juncture, multi-target molecular therapies could only be welcomed if their target
selectivity can be controlled to curb side effects and treatment uncertainties. Thus, there is
a niche in emerging biotechnologies for novel approaches to clean promiscuous drugs in
order to achieve a tighter specificity control. We have shown that such approaches are in
principle feasible by redesigning dirty drugs guided by novel selectivity filters (Fernández
et al., 2007; Demetri, 2007; Crunkhorn, 2008). Future developments will no doubt lead to
more effective ways of confining cross reactivity to targets of clinical relevance as better
structural markers for specificity are discovered. The drug-redesign exercise and the proof
of principle described here suggest that cleaning a dirty drug guided by basic new concepts
is in principle possible and will hopefully inspire further efforts in this regard.
Promiscuity might become a welcomed feature in kinase-inhibitor design but only
provided that cross reactivity can be held under tight control through the implementa-
tion of selectivity filters. We advocate that at least one such filter can be exploited ra-
tionally to enhance the specificity of promiscuous compounds, such as sunitinib, dasatinib,
EKB-569, sorafenib and erlotinib, towards their respective primary targets: KIT/VEGFR2,
ABL/SRC, EGFR, VEGFR2 and EGFR. This approach requires information subtler than a
structural characterization because it takes into account packing differences across targets.
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The dearth of structural information on available targets does not constitute a hindrance
to the applicability of this approach because packing information can be inferred directly
from sequence, by taking into account the fact that poorly wrapped regions of the structure
have a propensity to be disordered (Fernández and Berry, 2004; Pietrosemoli and Crespo,
2007).
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Figure 5.9: Affinity profile of the original/redesigned EKB-569 inhibitors. High-
throughput screening at 10 µM of original EKB-569 (blue) and redesigned EKB-569 (red)
over a battery of 228 human kinases displayed in a T7-bacteriophage-expressing library
(Ambit Bioscience, San Diego, CA). The screening assay of EKB-569 (blue) was used as
control. Hit values are reported as percentage bound kinase.
Bibliography
A. Agresti. An Introduction to Categorical Data Analysis, chapter 4: Logistic Regression.
Wiley Interscience, 1996.
J. Bain, M. McLauchlan, H. Eliott, and P. Cohen. The specificities of protein kinase in-
hibitors: an update. Biochem. J., 371:299–204, 2003.
J. M. Berg, J. L. Tymoczko, and L. Stryer. Biochemistry. W. H. Freeman and Company,
New York, 5th edition, 2002.
K. H. Bleicher, H. J. Böhm, Muller K., and A. I. Alanine. Hit and lead generation: beyond
high-throughput screening. Nat. Rev., 2:369–378, 2003.
M. A. Bogoyevitch and D. P. Fairlie. A new paradigm for protein kinase inhibition: block-
ing phosphorylation without directly targeting ATP binding. Drug Discov. Today, 12:
622–633, 2007.
R. Bonneau, C. E. Straus, C. A. Rohl, D. Chivian, P. Bradley, L. Malmstrom, T. Robertson,
and D. Baker. De novo prediction of three-dimensional structures for major protein
families. J. Mol. Biol., 322:65–78, 2002.
i
ii
C. Braken, L. M. Iakoucheva, P. R. Romero, and A. K. Dunker. Combining prediction,
computation and experiment for the characterization of protein disorder. Curr. Op. Str.
Biol., 14:570–576, 2004.
L. L. Brunton, J. S. Lazo, and K. L. Parker. Goodman & Gilman’s The Pharmacological
Basis of Therapeutics. McGraw-Hill Companies, 11th edition, 2005.
J. Chen, X. Zhang, and A. Fernández. Molecular basis for promiscuity and specificity in
the druggable kinome. Bioinformatics, 23:563–572, 2007.
D. Chivian, D. E. Kim, L. Malmstrom, J. Schonbrun, C. A. Rohl, and D. Baker. Prediction
of CASP6 structures using automated Robetta protocols. Proteins, 61:157–166, 2005.
C. Chothia. Hydrophobic bonding and accessible surface area in proteins. Nature, 248:
338–339, 1974.
A. Crespo and A. Fernández. Kinase packing defects as drug targets. Drug Discov. Today,
12:917–923, 2007.
S. Crunkhorn. Anticancer Drugs: Redesigning kinase inhibitors. Nat. Rev. Drug Disc., 7:
120–121, 2008.
J. Dancey and E. A. Sausville. Issues and progress with protein kinase inhibitors for cancer
treatment. Nat. ReV. Drug DiscoVery, 2:296–313, 2003.
G. D. Demetri. Structural reengineering of imatinib to decrease cardiac risk in cancer
therapy. J. Clin. Invest., 117:3650–3653, 2007.
iii
G. D. Demetri, M. V. Mehren, C. D. Blanke, A. D. Van den Abbeele, B. Eisenberg, P. J.
Roberts, M. C. Heinrich, D. A. Tuveson, S. Singer, M. Janicek, J. A. Fletcher, S. G.
Silverman, S. L. Silberman, R. Capdeville, B. Kiese, B. Peng, S. Dimitrijevic, B. J.
Druker, C. Corless, C. D. M. Fletcher, and H. Joensuu. Efficacy and safety of imatinib
mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 347:472–480,
2002.
A. B. Dietz, L. Souan, G. J. Knutson, M. R. Bulur, P. A. Litzow, and S. Vuk-Pavlovic´.
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity
in vivo. Blood, 104:1094–1099, 2004.
N. J. Donato and M. Talpaz. Clinical use of tyrosine kinase inhibitors: Therapy for chronic
myelogenous leukemia and other cancers. Cancer Res., 6:2965–66, 2000.
J. Drews. Drug Discovery: A Historical Perspective. Science, 287:1960–1964, 2000.
B. J Druker. Molecularly targeted therapy: have the floodgates opened? Oncologist, 9:
357–360, 2004.
C. Erlichman, M. Hidalgo, J. P. Boni, P. Martins, S. E. Quinn, C. Zacharchuk, P. Amorusi,
A. A. Adjei, and E. K. Rowinsky. Phase I Study of EKB-569, an irreversible inhibitor
of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin.
Oncol., 24:2232–2260, 2006.
H. Escriva, F. Delaunay, and Laudet V. Ligand binding and nuclear receptor revolution.
Bioessays, 22:357–360, 2000.
iv
D. Fabbro and C. G. Garcia-Echeverria. Targeting protein kinases in cancer therapy. Curr.
Opin. Drug Discovery Dev., 5:701–712, 2002.
M. A. Fabian, W. H. Biggs, D. K. Treiber, C. E. Atteridge, M. D. Azimioara, M. G.
Benedetti, T. D. Carter, Ciceri P., Edeen P. T., Floyd M., Ford J. M., Galvin M., Ger-
lach J. L., R. M. Grotzfeld, S. Herrgard, D. E. Insko, M. A. Insko1, Lai A. G., J-M
Lelias, S. A. Mehta, Z. V. Milanov, A. M. Velasco, L. M. Wodicka, H. K. Patel, P. P.
Zarrinkar, and D. J. Lockhart. A small molecule kinase interaction map for clinical
kinase inhibitors. Nat. Biotechnol., 23:329–336, 2005.
O. Fedorov, B. Marsden, V. Pogacic, P. Rellos, S. Müller, A. N. Bullock, J. Schwaller,
M. Sundström, and S. Knapp. A systematic interaction map of validated kinase inhibitors
with Ser/Thr kinases. Proc. Natl. Acad. Sci. U. S. A., 104:20523–20528, 2007a.
O. Fedorov, M. Sundström, B. Marsden, and S. Knapp. Insights for the development of
specific kinase inhibitors by targetd strcutural genomics. Drug Discov. Today, 12:365–
372, 2007b.
B. Y. Feng, A. Shelat, T. N. Doman, R. K. Guy, and B. K. Shoichet. High throughput
assays for promiscuous inhibitors. Nat. Chem. Biol., 1:146–148, 2005.
A. Fernández. Keeping dry and crossing membranes. Nat. Biotech., 22:1081–1084, 2004.
A. Fernández and R. S. Berry. Molecular dimension explored in evolution to promote
proteomic complexity. Proc. Natl. Acad. Sci. USA, 101:13460–13465, 2004.
A. Fernández and S. Maddipati. A priori inference of cross reactivity for drug-targeted
kinases. J. Med. Chem., 49:3092–3100, 2006.
vA. Fernández, A. Sanguino, Z. Peng, E. Ozturk, J. Chen, A. Crespo, S. Wulf, A. Shavrin,
C. Qin, J. Ma, J. Trent, Y. Lin, H. D. Han, L. S. Mangala, J. A. Bankson, J. Gelovani,
A. Samarel, W. Bornmann, A. K. Sood, and G. Lopez-Berestein. An anticancer C-kit
kinase inhibitor is re-engineered to make it more active and less cardiotoxic. Journal of
Clinical Investigation, 117:4044–4054, 2007.
A. Fernández and H. A. Scheraga. Insufficiently dehydrated hydrogen bonds as determinats
of protein interactions. Proc. Natl. Acad. Sci. U. S. A., 100:113–118, 2003.
A. Fernández, T. R. Sosnick, and A. Colubri. Dynamics of hydrogen bond desolvation in
protein folding. J. Mol. Biol., 321:659–675, 2002.
T. Force, D. S. Krause, and R. A. Van Etten. Molecular mechanisms of cardiotoxicity of
tyrosine kinase inhibition. Nat. Rev. Can., 7:332–344, 2007.
R. Fraczkiewicz and W. Braun. Exact and efficient analytical calculation of the accessible
surface areas and their gradient for macromolecules. J. Comput. Chem., 19:319–333,
1998.
S. Frantz. Drug discovery: playing dirty. Nature, 437:942–943, 2005.
A. Gabriele and G. L. King. Protein kinase C inhibitors in the treatment and prevention of
diabetic complications. Curr. Opin. Endocrinol. Diabetes, 8:197–204, 2001.
C. Gambacorti-Passerini, P. le Coutre, L. Mologni, M. Fanelli, C. Bertazzoli, E. Marchesi,
M. Di Nicola, A. Biondi, G. M. Corneo, D. Belotti, E. Pogliani, and N. B. Lydon. Inhi-
bition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells
and induces apoptosis. Blood Cells Mol. Dis., 23:380–394, 1997.
vi
J. Gibbs and A. Oliff. Pharmaceutical research in molecular oncology. Cell, 79:193–198,
1994.
J. D. Griffin. Interaction maps for kinase inhibitors. Nat. Biotech., 23:308–309, 2005.
T. Hampton. "Promiscuous" anticancer drugs that hit multiple targets may thwart resis-
tance. JAMA, 292:419 – 422, 2004.
D. G. Higgins, J. D. Thompson, and T. J Gibson. Using CLUSTAL for multiple sequence
alignments. Methods Enzymol., 266:383–402, 1996.
C. W. V. Hogue. Cn3D: a new generation of three-dimensional molecular structure viewer.
Trends Biochem. Sci., 22:314–316, 1997.
A. L. Hopkins, J. S. Mason, and J. P Overington. Can we rationally design promiscuous
drugs? Curr. Op. Struct. Biol., 16:127–136., 2006.
A. L. Hopkins, J. Ren, J. Milton, R. J. Hazen, J. H. Chan, D. I. Stuart, and D. K. Stammers.
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug
resistance properties. J. Med. Chem., 47:5912–5922, 2004.
M. Huse and J. Kuriyan. The conformational plasticity of protein kinases. Cell, 109:
275–282, 2002.
M. W. Karaman, S. Herrgard, D. K. Treiber, P Gallant, C. E. Atteridge, B. T. Campbell,
K. W. Chan, P. Ciceri, M. I. Davis, P. T. Edeen, R. Faraoni, M. Floyd, J. P. Hunt, D. J.
Lockhart, Z. V. Milanov, M. J. Morrison, G. Pallares, H. K. Patel, S. Pritchard, L. M.
vii
Wodicka, and P. P. Zarrinkar. A quantitative analysis of kinase inhibitor selectivity. Nat.
Biotech., 26:127–132, 2008.
C. T. Keith, A. A. Borisy, and B. R. Stockwell. Multicomponent therapeutics for networked
systems. Nat. Rev. Drug. Discov., 4:71–78, 2005.
R. Kerkela, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, C. Beahm, B. Walters, S. Shevtsov,
S. Pesant, F. J. Clubb, A. Rosenzweig, R. N. Salomon, R. A. Van Etten, J. Alroy, J.-B.
Durand, and T. Force. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Nat. Med., 12:908–916, 2006.
D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath. Docking and scoring in virtual
screening for drug discovery: methods and applications. Nat. Rev., 3:935–949, 2004.
Z. A. Knight and K. M. Shokat. Features of selective kinase inhibitors. Chemistry and
Biology, 12:621–637, 2005.
C. M. Krejsa, D. Horvath, S. L. Rogalski, J. E. Penzotti, B. Mao, F. Barbosa, and J. C.
Migeon. Predicting ADME properties and side effects: The BioPrint approach. Curr.
Opin. Drug. Discov. Devel., 6:470–480, 2003.
P. Kuhn, K. Wilson, M. G. Patch, and R. C. Stevens. The genesis of high-throughput
structure-based drug discovery using protein crystallography. Curr. Op. Chem. Biol., 6:
704–710, 2002.
T. Lengauer, C. Lemmen, M. Rarey, and M. Zimmermann. Novel technologies for virtual
screening. Drug Discovery Today, 9:27–34, 2004.
viii
A. Levitzki and A. Gazit. Tyrosine kinase inhibition: an approach to drug development.
Science, 267:1782–1788, 1995.
K. Liszewski. Drug discovery: Successful lead optimization strategies. Genetic Engineer-
ing and Biotechonology News, 26:14, 2006.
Y. Liu and N. S. Gray. Rational design of inhibitors that bind to inactive kinase conforma-
tions. Nat. Chem. Biol., 2:358–364, 2006.
P. D. Lyne. Structure-based virtual screening: an overview. Drug Discovery Today., 7:
1047–1055, 2002.
B. Ma, T. Elkayam, T. Wolfson, and R. Nussinov. Protein-protein interactions structurally
conserved residues distinguish between binding sites and exposed protein surfaces. Proc.
Natl. Acad. Sci. USA, 100:5772–7, 2003.
M. L. MacDonald, J. Lamerdin, S. Owens, B. H. Keon, G. K. Bilter, Z. Shang, Z. Huang,
H. Yu, J. Dias, T. Minami, S. W. Michnick, and J. K. Westwick. Identifying off-targets
effects and hidden phenotypes of drugs in human cells. Nat. Chem. Biol., 2:329–337,
2006.
G. Manning, D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. The protein kinase
complement of the human genome. Science, 298:1912–1934, 2002.
S. L. McGovern, B. T. Helfand, B. Feng, and B. K. Shoichet. A specific mechanism of
nonspecific inhibition. J. Med. Chem., 46:4265–4272, 2003.
ix
S. K. Mencher and L. G. Wang. Promiscuous drugs compared to selective drugs (promis-
cuity can be a virtue). BMC Clin. Pharmacol., 5:3–9, 2005.
M. Y. Mizutani and A. Itai. Efficient method for high-throughput virtual screening based
on flexible docking: Discovery of novel acetylcholinesterase inhibitors. J. Med. Chem.,
47:4818–4828, 2004.
M. Y. Mizutani, Y. Takamatsu, T. Ichinose, K. Nakamura, and A. Itai. Effective handling
of induced-fit motion in flexible docking. PROTEIN: Structure, Function, and Bioinfor-
matics., 63:878–891, 2006.
M. R. Myers, W. He, and C. Hulme. Inhibitors of tyrosine kinases involved in inflammation
and autoimmune disease. Curr. Pharm. Des., 3:473–502, 1997.
David L. Nelson and Michael M. Cox. Principles of Biochemistry. W. H. Freeman and
Company, New York, 4th edition, 2005.
M. E. M. Noble, J. A. Endicott, and L. N. Johnson. Protein kinase inhibitors: insights into
drug design from structure. Science, 303:1800–1805, 2004.
T. Ooi, M. Oobatake, G. Nemethy, and H. A. Scheraga. Accessible surface area as a
measure of the thermodynamic parameters of hydration of peptides. Proc. Natl. Acad.
Sci. USA, 84:3086–3090, 1987.
T. I. Oprea and H. Matter. Integrating virtual screening in lead discovery. Curr. Op. Chem.
Biol., 8:349–358, 2004.
J. Owens. Screening: Dirty drugs’ secrets uncovered. Nat. Rev. Drug Discov., 5:542, 2006.
xN. Pietrosemoli and A. Crespo, A.and Fernandez. Dehydration propensity of order-
disorder intermediate regions in soluble proteins. J. Proteome Res., 6:3519–3526, 2007.
G. M. Rishton. Failure and success in modern drug discovery: Guiding principles in the
establishment of high probability of success drug discovery organizations. Med. Chem.,
1:519–527, 2005.
W. M. Rockey and A. H. Elcock. Rapid computational identification of the targets of
protein kinase inhibitors. J. Med. Chem., 48:4138–4152, 2005.
B. L. Roth, D. J. Sheffler, and W. K. Kroeze. Magic shotguns versus magic bullets: selec-
tively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov.,
3:353–359, 2004.
T. Schindler, W. Bornmann, P. Pellicena, W. T. Miller, B. Clarkson, and J Kuriyan. Struc-
tural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science, 289:1938–
1942, 2000.
S. P. Shenkin, B. Erman, and L. D. Mastrandrea. Information-theoretical entropy as a
measure of sequence variability. Proteins: Struct. Funct. Genet., 11:297–313, 1991.
B. B. Shoichet. Virtual screening of chemical libraries. Nature, 432:862–865, 2004.
S. S. Taylor and E. Radzio-Andzelm. Protein kinase inhibition: natural and synthetic
variations on a theme. Curr. Opin. Chem. Biol., 1:219–226., 1997.
R. Tibes, J. Trent, and R. Kurzrock. Tyrosine kinase inhibitors and the dawn of molecular
cancer therapeutics. Annu. Rev. Pharmacol. Toxicol., 45:357–384, 2005.
xi
C. J. Torrance, P. E. Jackson, E. Montgomery, K. W. Kinzler, B. Vogelstein, A. Wissner,
M. Nunes, P. Frost, and C. M. Discafani. Combinatorial chemoprevention of intestinal
neoplasia. Nat. Med., 6:1024–1028, 2000.
M. Vieth, R.E. Higgs, D.H. Robertson, M. Shapiro, E.A. Gragg, and H. Hemmerle.
Kinomics-structural biology and chemogenomics of kinase inhibitors and targets.
Biochim. Biophys. Acta, 1697:243–257, 2004.
P. J. Whittle and T. L. Blundell. Protein structure-based drug design. Annu. Rev. Biophys.
Biomol. Str., 23:349–375, 1994.
A. Wissner, E. Overbeek, M. F. Reich, M. B. Floyd, B. D. Johnson, N. Mamuya, E. C. Ros-
fjord, C. Discafani, R. Davis, X. Shi, S. K. Rabindran, B. C. Gruber, F. Ye, W. A. Hallett,
R. Nilakantan, R. Shen, Y.-F. Wang, L. M. Greenberger, and H.-R. Tsou. Synthesis and
structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles.
the design of an orally active, irreversible inhibitor of the tyrosine kinase activity of
the epidermal growth factor receptor (EGFR) and the human epidermal growth factor
receptor-2 (HER-2). J. Med. Chem., 46:49–63, 2003.
